

Multi-Drug Rapid Test Panel (Urine)

Cocaine (COC 300) for the summary.

esult when the Metha

ne is 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH).

(SA).: darijuana (THC50) the full darijuana (THC50) the Multi-Drug Rapid Test Panel yields a positive result when the concentration of THC-COOH in urine exceeds 50ng/mL. See Marijuana

Marijuana (THC25)
The Multi-Drug Rapid Test Panel yields a positive result when the concentration of THC-COOH in urine exceeds 25ng/mL. See Marijuana

THC150) for the summary.

Marijuana (THC20)

Marijuana (THC20)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of THC-COOH in urine exceeds 20 ng/mL. See Marijuana

Methadone is a long acting pain reliever producing effects that last from twelve to forty-eight hours. Ideally, methadone frees the client from

Memadone is a long acting pain relever producing effects that last riom weeve to forty-eight nouts, locally, memadone ir retes the client from the pressures of obtaining lilegal heroin, from the dangers of injection, and from the emotional roller coaster that most opiates produce. Methadone, if taken for long periods and at large doses, can lead to a very long withdrawal period. The withdrawals from methadone are more prolonged and troublesome than those provoked by heroin cessation, yet the substitution and phased removal of methadone is an acceptable method of detoxification for patients and therapists. The Multi-Drug Rapid Test Panel yields a positive result when the concentration of methadone in urine exceeds 300ng/mL At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for methadone

Substance rouse and months of the constituence of the constituence

Methamphetamine is an addictive stimulant drug that strongly activates certain systems in the brain. Methamphetamine is closely related

chemically to Amphetamine, but the central nervous system effects of Methamphetamine are greater. Methamphetamine is made in illega

abbratories and has a high potential for abuse and dependence. The drug can be taken orally, injected, or inhaled. Acute higher doses ead to enhanced stimulation of the central nervous system and induce euphoria, alertness, reduced appetite, and a sense of increased anergy and power. Cardiovascular responses to Methamphetamine include increased blood pressure and cardiac arrhythmias. More acute esponses produce anxiety, paranola, hallucinations, psychotic behavior, and eventually, depression and exhaustion.

responses produce anxiety, paranola, hallucinations, psychotic behavior, and eventually, depression and exhaustion. The effects of Methamphetamine generally last 2-4 hours and the drug have a half-life of 9-24 hours in the body. Methamphetamine is excreted in the urine primarily as Amphetamine, and oxidized and deaminated derivatives. However, 10-20% of Methamphetamine is excreted unchanged. Thus, the presence of the parent compound in the urine indicates Methamphetamine use. Methamphetamine is generally detectable in the urine for 3-5 days, depending on urine pH level. The Multi-Drug Rapid Test Panel is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal ambody to selectively detect elevated levels of Methamphetamine in urine. The Multi-Drug Rapid Test Panel yields a positive

Methamphetamine (MET 500)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Methamphetamine in urine exceeds 500ng/mL. See Methamphetamine (MET 1000) for the summary.

Methamphetamine (MET 300)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Methamphetamine in urine exceeds 300ng/mL. See Methamphetamine (MET 1000) for the summary.

Methylenedioxymethamphetamine (MDMA500)

Methylenedioxymethamphetamine (MDMA500)

general opinion is that this is a secondary effect of the drug (Nichols and Oberlender, 1990). The most pervasive effect of MDMA, occurring

Methylenedioxymethamphetamine (MDMA1,000)
The Multi-Drug Rapid Test Panel yields a positive result when the concentration of methylenedioxymethamphetamine in urine exceeds 1,000ng/mL. See methylenedioxymethamphetamine (MDMA500) for the summary.

Methylenedioxymethamphetamine (MDMA250)
The Multi-Drug Rapid Test Panel yields a positive result when the concentration of methylenedioxymethamphetamine in urine exceeds 250ng/mL. See methylenedioxymethamphetamine (MDMA500) for the summary.

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of methylenedioxymethamphetamine in urine exceeds

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of morphine (MOP 300)

Morphine (MOP 300)

Opiate refers to any drug that is derived from the opium poppy, including the natural products, morphine and codeine, and the semi-synthetic drugs such as heroin. Opioid is more general, referring to any drug that acts on the opioid receptor.

Opioid analgesics comprise a large group of substances which control pain by depressing the CNS. Large doses of morphine can produce higher tolerance levels, physicological dependency in users, and may lead to substance abuse. Morphine is excreted unmetabolized, and is also the major metabolic product of codeine and heroin. Morphine is detectable in the urine for several days after an optate dose.²

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of morphine in urine exceeds 300ng/mL.

Morphine (MOP 100)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of morphine in urine exceeds 100ng/mL. See Morphine (MOP300) for the summary.

MOP300) for the summary.

Morphine/Dipate (OPI 2,000)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of morphine in urine exceeds 2,000ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA). See morphine (MOP 300) for summary.

Morphine/Opiate (OPI 1,000)
The Multi-Drug Rapid Test Panel yields a positive result when the concentration of morphine in urine exceeds 1,000ng/mL. This is the

USA). See morphine (MOP 300) for summary.

Methaqualone (MOL)

Methaqualone (MOL)

Methaqualone (Quaalude, Sopor) is a quinazoline derivative that was first synthesized in 1951 and found clinically effective as a sedative and hypnotic in 1956. "If soon gained popularity as a drug of abuse and in 1984 was removed from the US market due to extensive misuse. It is occasionally encountered in illicit form, and is also available in European countries in combination with dipherhydramine (Mandrax).

Methaqualone is extensively metabolized in vivo principally by hydroxylation at every possible position on the molecule. At least 12 exabellates they been (deeplified in the valide).

Phencyclidine, (PCP)
Phencyclidine, also known as PCP or Angel Dust, is a hallucinogen that was first marketed as a surgical anesthetic in the 1950's. It was removed from the market because patients receiving it became delirious and experienced hallucinations.
PCP is used in powder, capsule, and tablet form. The powder is either snorted or smoked after mixing it with marijuana or vegetable matter.
PCP is most commonly administered by inhaliation but can be used intravenously, intra-nasally, and orally. After low doses, the user thinks and acts swiftly and experiences mood swings from euphoria to depression. Self-injurious behavior is one of the devastating effects of PCP.

CP can be found in urine within 4 to 6 hours after use and will remain in urine for 7 to 14 days, depending on factors such as metabolic ate, user's age, weight, activity, and diet.6 PCP is excreted in the urine as an unchanged drug (4% to 19%) and conjugated metabolites

(25% to 30%).9

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of phencyclidine in urine exceeds 25 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).

Propoxyphene (PPX) is a narcone analgesic compound bearing structural similarity to methadone. As an analgesic propoxyphene can be from 50-75% as potent as oral codeine. Darrocet¹⁴, one of the most common brain anness for the drug, contains 50-100 mg of propoxyphene napsylate and 325-650 mg of acetaminophen. Peak plasma concentrations of propoxyphene are achieved from 1 to 2 hours post dose. In the case of overdose, propoxyphene blood concentrations can reach significantly higher levels. In humans, propoxyphene is metabolized by N-demethylation to yield norpropoxyphene. Norpropoxyphene has a longer half-life (30 to 36 hours) than parent propoxyphene (6 to 12 hours). The accumulation of norpropoxyphene seen with repeated doses may be largely responsible for resultant loxicity.

he Multi-Drug Rapid Test Panel yields a positive result when the concentration of Propoxyphene or Norpropoxyphene in urine exceeds 00 ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended

revair. A fritegiressants (1CA)
AC (Tricyclic Antidepressants) are commonly used for the treatment of depressive disorders. TCA overdoses can result in profound CNS opression, cardiotoxicity and anticholinergic effects. TCA overdose is the most common cause of death from prescription drugs. TCAs are ken orally or sometimes by injection. TCAs are metabolized in the liver. Both TCAs and their metabolities are cereted in urine mostly in

Transadol (TNA) is a quasi-narcotic analgesic used in the treatment of moderate to severe pain. It is a synthetic analog of codeine, but has a low binding affinity to the mu-opioid receptors. Large doses of transado can develop tolerance and physiological dependency and lead to its abuse. Transado is extensively metabolized after oral administration. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% is excreted as metabolites. The major pathways appear to be N- and O- demethylation, glucoronidation or autificine as the contraction.

soliation in the liver.

The Multi-Drug Rabid Test Panel is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Tramadol in urine. The Multi-Drug Rapid Test Panel yields a positive result when Tramadol in urine exceed 100ng/mL.

the Multi-Drug Rapid Test Panel yields a positive result when the concentration of Ketamine in urine exceeds 500ng/mL. See

Oxycodone is a semi-synthetic opioid with a structural similarity to codeine. The drug is manufactured by modifying the baine, an alkaloid

(RET1,000) for the summary.

et (RET300)

ti-Drug Rapid Test Panel yields a positive result when the concentration of Ketamine in urine exceeds 300ng/mL. See et (KET1,000) for the summary.

ene (PPX) is a narcotic analgesic compound bearing structural similarity to methadone. As an analgesic, propo

metabolites have been identified in the urine.

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Methaqualone in urine exceeds 300ng/mL-Phencyclidine (PCP)

sted screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, See morphine (MOP 300) for summary.

Methylenedioxymethamphetamine (MDMA500)
Methylenedioxymethamphetamine (ecstasy) is a designer drug first synthesized in 1914 by a German drug company for the t
obesity. Those who take the drug frequently report adverse effects, such as increased muscle tension and sweating. MDMA is
a stimulant, although it has, in common with amphetamine drugs, a capacity to increase blood pressure and heart rate. No
produce some perceptual changes in the form of increased sensitivity to light, difficulty in focusing, and burred vision in som
mechanism of action is thought to be via release of the neurotransmitter serotonin. MDMA may also release dopamine, a

in virtually all people who took a reasonable dose of the drug, was to produce a clenching of the laws. The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Methylenedioxymethamphetamine is 500ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a screening cut-off for Methylenedioxymethamphetamine positive specimens. Methylenedioxymethamphetamine (MDMA 1,000)

etamine in urine exceeds 1.000ng/mL.

methamphetamine (MDMA300)

screening cut-off for propoxyphene positive specimens.

Fricyclic Antidepressants (TCA)

FCA (Tricyclic Antidepressants) are commonly used for

ine (KET500)

iction Sheet for testing of any combination of the following drugs:

BAR/BZO/BUP/COC/THC/MTD/MET/MDMA/MOP/MQL/OPI/PCP/PPX/TCA/TRA/KET/OXY/COT/EDDP/FYL/K2/ETG/K2+/ZOL/M

Itaneous, qualitative detection of multiple drugs and drug metabolites in human urine .For healthcare prol at point of care sites. Immunoassay for invitro diagnostic use only.

[INTENDED USE] The Multi-Drug Rapid Test Panel is a rapid chromatographic immunoassay for the qualitative detection of multiple drugs and drug metabolites in urine at the following cut-off concentrations:

Test	Calibrator	Cut-off (ng/mL)
Amphetamine (AMP1,000)	d-Amphetamine	1,000
Amphetamine (AMP 500)	d-Amphetamine	500
Amphetamine (AMP 300)	d-Amphetamine	300
Barbiturates (BAR 300)	Secobarbital	300
Barbiturates (BAR 200)	Secobarbital	200
Benzodiazepines (BZO 500)	Oxazepam	500
Benzodiazepines (BZO 300)	Oxazepam	300
Benzodiazepines (BZO 200)	Oxazepam	200
Benzodiazepines (BZO 100)	Oxazepam	100
Buprenorphine (BUP)	Buprenorphine	10
Cocaine (COC 300)	Benzoylecgonine	300
Cocaine (COC150)	Benzoylecgonine	150
Cocaine (COC 100)	Benzoylecgonine	100
EDDP300	2-ethylidene-1,5-dimethyl- 3,3-diphenylpyrrolidine	300
EDDP100	2-ethylidene-1,5-dimethyl- 3,3-diphenylpyrrolidine	100
Ethyl Glucuronide (ETG)	Ethyl Glucuronide	500
Marijuana (THC150)	11-nor-Δ9-THC-9 COOH	150
Marijuana (THC 50)	11-nor-Δ9-THC-9 COOH	50
Marijuana (THC 25)	11-nor-Δ9-THC-9 COOH	25
Marijuana (THC 20)	11-nor-Δ9-THC-9 COOH	20
Mephedrone (MEP)	Mephedrone	500
Methadone (MTD 300)	Methadone	300
Methadone (MTD 200)	Methadone	200
Methamphetamine (MET 1,000)	d-Methamphetamine	1,000
Methamphetamine (MET 500)	d-Methamphetamine	500
Methamphetamine (MET 300)	d-Methamphetamine	300
Methcathinone (MCAT)	Methcathinone	1,000
Methylenedioxymethamphetamine (MDMA 500)	d,I-Methylenedioxymethamphetamine	500
Methylenedioxymethamphetamine (MDMA 1,000)	d,I-Methylenedioxymethamphetamine	1,000
Methylenedioxymethamphetamine (MDMA 250)	d,I-Methylenedioxymethamphetamine	250
Methylenedioxymethamphetamine (MDMA 300)	d,I-Methylenedioxymethamphetamine	300
Morphine (MOP 300)	Morphine	300
Morphine (MOP 100)	Morphine	100
Methaqualone (MQL)	Methaqualone	300
Opiate (OPI 2,000)	Morphine	2,000
Opiate (OPI 1,000)	Morphine	1,000
Phencyclidine (PCP)	Phencyclidine	25
Propoxyphene (PPX)	Propoxyphene	300
Tricyclic Antidepressants (TCA)	Nortriptyline	1,000
Tramadol (TRA)	Tramadol	100
Ketamine (KET 1,000)	Ketamine	1,000
Ketamine (KET 500)	Ketamine	500
Ketamine (KET 300)	Ketamine	300
Oxycodone (OXY)	Oxycodone	100
Cotinine (COT200)	Cotinine	200
Cotinine (COT100)	Cotinine	100
Fentanyl (FYL20)	Norfentanyl	20
Fentanyl (FYL10)	Norfentanyl	10
Synthetic Marijuana (K2-50)	JWH-073,JWH-018	50
Synthetic Marijuana (K2-30)	JWH-073,JWH-018	30
Synthetic Marijuana (K2+)	AB-PINACA pentanoic acid metabolite	10
UR-144	UR-144 5-Pentanoic acid metabolite	25
Zolpidem (ZOL)	Zolpidem	50
		$\overline{}$

Lysergic acid diethylamide(LSD)

Configurations of the Multi-Drug Rapid Test Panel come with any combination of the above listed drug analytes. This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Assort of the consideration of the above listed drug analytes. This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatographylmass spectrometry (GG/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

[SUMMARY]

The Multi-Drug Rapid Test Panel is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes reported and adultion of the above the control of the control of the above the section of the above time and the section of the section of the above time and the section of the above time a

Amphetamine (AMP 1,000)

Amphetamine (AMP 1,000)
Amphetamine is a Schedule II controlled substance available by prescription (Dexedrine®) and is also available on the illicit market.
Amphetamines are a class of potent sympathomimetic agents with therapeutic applications. They are chemically related to the human body's natural catecholamines: epinephrine and norepinephrine. Acute higher doses lead to enhanced stimulation of the central nervous system (CNS) and induce euphoria, alertness, reduced appellet, and a sense of increased energy and power. Cardiovascular responses to amphetamines include increased blood pressure and cardiac arrhythmias. More acute responses produce anxiety, paranoia,

for the summary.

Barbiturates (BAR 300)

Barbiturates (BAR 300)

Barbiturates are CNS depressants. They are used therapeutically as sedatives, hypnotics, and anticonvulsants barbiturates are almost always taken orally as capsules or tablets. The effects resemble those of intoxication with alcohol. Chronic use of barbiturates leads to tolerance and physical dependence.

Short-acting barbiturates taken at 400 mg/day for 2-3 months can produce a clinically significant degree of physical dependence. Withdrawal symptoms experienced during periods of drug abstinence can be severe enough to cause death.

Only a small amount (less than 5%) of most barbiturates are excreted unaltered in the urine.

summary.

Benzodiazepines (BZO 500)

Benzodiazepines are medicati) stions that are frequently prescribed for the symptomatic treatment of anxiety and sleep disorders. They

roduce their effects via specific receptors involving a neurochemical called gamma aminobutyric acid (GABA). Because they are safer and nore effective, benzodiazepines have replaced barbiturates in the treatment of both anxiety and insomnia. Benzodiazepines are also used produce their effects via specific rec

conjugated drug. The detection period for benzodiazepines in urine is 3-7 days.

The Multi-Turg Rapid Test Panel yields a positive result when the concentration of oxazepam in urine exceeds 500ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for

Benzodiazepines (BZO 300)
The Multi-Drug Rapid Test Panel yields a positive result when oxazepam in urine exceed 300ng/mL. See Benzodiazepines (BZO 500) for

he summary.

The Multi-Drug Rapid Test Panel yields a positive result when oxazepam in urine exceed 100ng/mL. See Benzodiazepines (BZO 500) for

Buprenex[™]. Temgesic[™] and Suboxone[™]. which contain Buprenorphine HCl alone or in combination with Naloxone HCl. Therapeuticall Buprenorphine is used as a substitution treatment for opioid addicts. Substitution treatment is a form of medical care offered to opia addicts (primarily heroin addicts) based on a similar or identical substance to the drug normally used. In substitution therap

Buprenorphine is as effective as Methadone but demonstrates a lower level of physical dependence. Concentrations of free Buprenorphine and Norbuprenorphine in urine may be less than 1 ng/ml after therapeutic administration, but can range up to 20 ng/ml in abuse situations. The plasma half-life of Buprenorphine is 2-4 hours. While complete elimination of a single dose of the drug can take as long as 6 days, the window of detection for the parent drug in urine is thought to be approximately 3 days.

Substantial abuse of Buprenorphine has also been reported in many countries where various forms of the drug are available. The drug has

been diverted from legitimate channels through theft, doctor shopping, and fraudulent prescriptions, and been abused via intra sublingual, intranasal and inhalation routes. The Multi-Drug Rapid Test Panel yields a positive result when the Buprenorphine in urine exceeds 10ng/mL.

cocaine is a potent central nervous system stimulant and a local anesthetic. Initially, it brings about extreme energy and rest gradually resulting in tremors, over-sensitivity and spasms. In large amounts, cocaine causes fever, unresponsivenes

breathing and unconsciousness.

Cocaine is often self-administered by nasal inhalation, intravenous injection and free-base smoking. It is excreted in the urine in a short time primarily as benzoyleogonine.^{3,4} Benzoyleogonine, a major metabolite of cocaine, has a longer biological half-life (5-8 hours) than cocaine (0.5-1.5 hours), and can generally be detected for 24-48 hours after cocaine exposure.⁴

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of benzoyleogonie in urine exceeds 300ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, 100.5).

USA).* Cocaine (COC 150)

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of benzoylecgonine in urine exceeds 150ng/mL. See Cocaine (COC 300) for the summary. Cocaine (COC 100)
The Multi-Drug Rapid Test Panel yields a positive result when the concentration of benzoylecgonine in urine exceeds 100ng/mL. See

system (CNS) and induce eupnoria, areriness, reduced appetite, and a sense of measurement of the armonic amphetamines include increased blood pressure and cardiac arrhythmias. More acute responses produce anxiety, paranoia, hallucinations, and psychotic behavior. The effects of Amphetamines generally last 2-4 hours following use and the drug has a half-life of 4-24 hours in the body. About 30% of amphetamines are excreted in the urine in unchanged form, with the remainder as hydroxylated and

deaminated derivatives.

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of amphetamines in urine exceeds 1,000ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHRA USA).

Amphetamine (AMP 500)
The Multi-Drug Rapid Test Panel yields a positive result when amphetamines in urine exceed 500ng/mL. See Amphetamine (AMP 1,000)

for the summary.

Amphetamine (AMP 300)

The Multi-Drug Rapid Test Panel yields a positive result when amphetamines in urine exceed 300ng/mL. See Amphetamine (AMP 1,000) for the summary.

nate detection time limits for barbiturates are:

The approximate detection time limits for deroflurates are:

Short acting (e.g. Secobarbital)

Long acting (e.g. Phenobarbital)

100 mg PO (oral)

4.5 days

7 days²

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of secobarbital in urine exceeds 300ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for Barbiturate

Substance values and wenter require territors Administration (Swin 197) does not have a recommended screening current of Darmonate positive specimens.

Barbiturates (BAR 200)

The Multi-Drug Rapid Test Panel yields a positive result when secobarbital in urine exceed 200ng/mL. See Barbiturates (BAR 300) for the

(etamine(KET1,000) mine(KET1,000)
mine is a dissociative anesthetic developed in 1963 to replace PCP (Phencyclidine). While Ketamine is still used in human anesthesia veterinary medicine, it is becoming increasingly abused as a street drug. Ketamine is molecularly similar to PCP and thus creates ar effects including numbness, loss of coordination, sense of invulnerability, muscle rigidity, aggressive / violent behavior, slurred or ked speech, exaggerated sense of strength, and a blank stare. There is depression of respiratory function but not of the central an eleves speech, exaggerated series or streight, and a dam's salet, rifer is operationally fundant out not in the cellinal antervous system, and cardiovascular function is maintained. The effects of Ketamine generated plast 4-6 hours following use. Ketamine is excerted in the urine as unchanged drug (2.3%) and netabolities (98.5%). The Multi-Drug Rapid Test Panel is a rapid urine screening fest that can be performed without the use of an instrument. The test utilizes a nonoclonal antibody to selectively detect elevated levels of Ketamine in urine. The Multi-Drug Rapid Test Panel yields a positive result when Ketamine in urine exceeded 1,000mg/mL.

more effective, penzoolazepines nave repiacob paroitruates in the treatment of both anxiety and insomma. Benzoolazepines are also used as sedatives before some surjical and medical procedures, and for the treatment of seizure disorders and alcohol withdrawal. Risk of physical dependence increases if benzodiazepines are taken regularly (e.g.,daily) for more than a few months, especially at higher than normal doses. Stopping abruptly can bring on such symptoms as trouble sleeping, gastrointestinal upset, feeling unwell, loss of appetite, sweating, trembling, weakness, anxiety and changes in perception. Only trace amounts (less than 1½) of most benzodiazepines are excreted unaltered in the urine; most of the concentration in urine is conjugated drug. The detection period for benzodiazepines in urine is 3-7 days.

Oxycodone is a semi-synthetic opioid with a structural similarity to coolenie. The origin is manufactured by modifying the plane, an alkalor found in the opioim poppy. Oxycodone, like all opiate agonists, provides pain relief by acting on opioid receptors in the spinal cord, brain, and possibly directly in the affected tissues. Oxycodone is prescribed for the relief of moderate to high pain under the well-known pharmaceutical trade names of OxyContine, Tylox08, Percodar@ and Percocet®. While Tylox08, Percodar@ Percocet® contain only small doses of oxycodone hydrochloride combined with other analgesics such as acetaminophen or aspirin, OxyContin consists solely of oxycodone in the analgesics such as acetaminophen or aspirin, OxyContin consists solely of oxycodone. In a 24-hour urine, 33-61% of a single, 5 mg oral dose is excreted with the primary constituents being unchanged drug (13-19%), conjugated drug (7-29%) and conjugated oxymorphone (13-14%). The window of detection for Oxycodone in urine is expected to be similar to that of other opioids such as morphine.

The Multi-Drug Rapid Test Panel is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Oxycodone in urine. The Multi-Drug Rapid Test Panel yields a positive result when Oxycordone in urine expression. Benzodiazepines (BZO 200)
The Multi-Drug Rapid Test Panel yields a positive result when oxazepam in urine exceed 200ng/mL. See Benzodiazepines (BZO 500) for

one in urine exceeds 100ng/mL

Cotinine (COT 200)

Cotinine is the first-stage metabolite of nicotine, a toxic alkaloid that produces stimulation of the autonomic ganglia and central nervous system when in humans. Nicotine is a drug to which virtually every member of a tobacco-smoking society is exposed whether through direct contact or second-hand inhalation. In addition to tobacco, nicotine is also commercially available as the active ingredient in smoking replacement therapies such as nicotine gum, transdermal patches and nasal sprays.

In a 24-hour urine, approximately 5% of a nicotine dose is excreted as unchanged drug with 10% as cotinine and 35% as hydroxycotinine; the concentrations of other metabolites are believed to account for less than 5%. "White cotinine is thought to be an inactive metabolite, it's elimination profile is more stable than that of nicotine which is largely urine pH dependent. As a result, cotinine is considered a good biological marker for determining nicotine use. The plasma half-life of nicotine is approximately 60 minutes following inhalation or parenteral administration. "Nicotine and cotinine are rapidly eliminated by the kidney; the window of detection for cotinine in urine at a cutoff level of 200ng/mL is expected to be up to 2-3 days after nicotine use.

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Cotinine in urine exceeds 200ng/ml.

Cotinine (COT 100)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Cotinine in urine exceeds 100ng/mL. See

Cotinine(COT200) for the summary.

2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP 300)

Methadone is an unusual drug in that its primary urinary metabolites (EDDP and EMDP) are cyclic in structure, making them very difficult to detect using immunoassays targeted to the native compound. "Exacerbating this problem, there is a subsection of the population classified as "extensive metabolizers" of methadone. In these individuals, a urine specimen may not contain enough parent methadone to yield a positive drug screen even if the individual is in compliance with their methadone maintenance. EDDP represents a better urine marker for methadone maintenance than unmetabolized methadone.

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of EDDP in urine exceeds 300ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for EDDP possibly experiences.

2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP 100) The Multi-Drug Rapid Test Panel yields a positive result when the concentration of EDDP in urine exceeds 100ng/mL. See EDDP 300 for

THE (a8-tetrahydrocannabinol) is the primary active ingredient in cannabis (marijuana). When smoked or orally administered, THC produces euphonic effects. Users have impaired short-term memory and slowed learning. They may adso sperience transient episodes of confusion and anxiety. Long-term, relatively heavy use may be associated with behavioral disorders. The peak effect of marijuana administered by smoking occurs in 20-30 minutes and the duration is 90-120 minutes after one cigarette. Elevated levels of universabilities are found within hours of exposure and remain detectable for 3-10 days after smoking. The main metabolitie excreted in the tarity (1-120) larny, belongs to powerful narcotics analgesics, and is a μ special opiates receptor stimulant. Fentanyl is one of the varieties that beer d in management of United Nations "Single Convention of narcotic drug in 1961", Among the opiates agents that under internations for, lentanyl is one of the most commonly used to cure moderate to severe pain. After continuous injection of fentanyl, the sufferer wi ance of protracted opioid abstinence syndrome, such as ataxia and irritability etc^{2,3}, which presents the addiction afte urine is 11-nor-ay-terranyorocannapinor-y-carooxylic acid (1HC-OODH).

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of THC-COOH in urine exceeds 150ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA,

lave the performance of protracted opioid abstinence syndrome, such as ataxia and uniquing etc. ", which presents the additional addition and amphetamine, furg addition to take fentanty mainly have got the possibility of higher infection rate of HIV, more dangerous injection behavior and more lifelong medication overdose. The FYL Rapid Test Panel (Urine) is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a noncolonal antibody to selectively detect elevated levels of norfentanyl in urine. The FYL Rapid Test Panel (Urine) yields a positive result when norfentanyl in urine exceeds 20ng/mL. Fentanyl (FYL10)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Norfentanyl in urine exceeds 10ng/mL. See FYL20 for

to summary.

ynthetic Marijuana (K2-50)

ynthetic Marijuana or K2 a psychoactive herbal and chemical product that when consumed, mimics the effects of Marijuana. It is best ynthetic Marijuana or K2 and Spice, both of which have largely become genericized trade marks used to refer to any synthetic under the product. The studies suggest that synthetic marijuana intoxication is associated with acute psychosis, worsening of previously stable psychotic disorders, and also may have the ability to trigger achronic (long-term) psychotic disorder among vulnerable individual

such as those with a family history of mental illness.

Elevated levels of urinary metabolites are found within hours of exposure and remain detectable for 72 hours after smoking (depending on usage/dosage). As of March 1, 2011, five cannabinoids, JWH -018, JWH-073, CP-47, JWH-200and cannabicyclo hexanol are now illegal in the US because these substances have the potential to be extremely harmful and, therefore, pose an imminenthazard to the public

The Multi-Drug Rapid Test Panel yields a positive result when the synthetic marijuana metabolite in urine exceeds 50ng/mL Synthetic Marijuana (K2-30)
The Multi-Drug Rapid Test Panel yields a positive result when the concentration of the synthetic marijuana metabolite in urine exceeds 30ng/mL. See K2-50 for the summary.

Ethyl Glucuronide (ETG 500)

Ethyl glucuronide (ETG) is a metabolite of ethyl alcohol which is formed in the body by glucuronidation following exposure to ethanol usually from drinking alcoholic beverages. After Alcohol is absorbed by the body, 90-95% Alcohol is oxidized with the help of emzyn Only 0.5%-1.5% Alcohol integrates with glucose into Ethyl Gluconide. ETG remains in urine longer period than Alcohol. When Alcohol volume is drunk (such as 0.1g/kg), ETG detection window varies from 13 - 20hours after drinking. However, maximum 8

w can be 80 hours for high Alcohol volume drinking The Multi-Drug Rapid Test Panel yields a positive result when the Ethyl Glucuronide in urine exceeds 500ng/mL. Synthetic Marijuana (K2+)

Synthetic cannabinoids are designer drugs that are structurally different from THC (the active component of cannabis) but act in similar ways to affect the cannabinoid receptor system in the brain. Over the past few years, this class of designer drugs has mainstreamed to secone globally popular and increasingly problematic. Synthetic cannabinoids fall into seven major structural groups:

1. Naphthoylindoies (e.g. WH-018, WH-073)

Naphthoylindoles (e.g., JWH-018, JWH-073)
 Naphthymethylindoles (JWH-175, JWH-184, JWH-185, JWH-199)
 Naphthylypyroles (JWH-145, JWH-144, JWH-147, etc)
 Naphthylindthylindones (JWH-176)
 Phenylacetylindoles (JWH-250, JWH-251, JWH-302)
 Cyclohexylphenols (e.g. CP 47,497)
 Obberzopyrans (classic cannabinold structure such as. HU-210 and HI

oid structure such as. HU-210 and HU-211)

w structural group: Aminoalkylindazoles (AB-PINACA, AB-FUBINACA, AB-CHMINACA, etc)In their original, chemical state, synthetic New structural group: Aminoalkylindazoles (AB-PINACA, AB-FUBINACA, AB-CHMINACA, etc)In their original, chemical state, synthetic cannabinoids are liquid. The drugs are usually sold combined with dried herbs that emulate marijuana and are intended for smoking although powdered versions are also available. As laws are written to control these drugs with each new synthetic cannabinoid class as they are introduced to the market, the older versions (MH-018, MH-073) are seen less frequently than years past. The current trend shows the aminoalkylindazole based drugs such as AB-PINACA, AB-FUBINACA and AB-CHMINACA. The Synthetic Marijuana K2+(AB-Pinaca) Rapid Test Panel (Urine) is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Synthetic Marijuana K2+(AB-Pinaca) Rapid Test Panel (Urine) yields a positive result when the AB-PINACA pentanoic acid metabolite in urine exceeds 10xe6.

diazepine hypnotic sold under the trade names Ambien®, Stilnox® and Edluar® for the treatment of inam is a non-benzodiazepine hypnotic sold under the trade names Ambiened, Sulhake em has not adequately demonstrated effectiveness in maintaining sleep, unless de rer, it is effective in initiating sleep, tworks quickly, usually within 15 minutes, and has a

short half-life of 2-3 hours. Because the characteristic of quick effect, low side effect, etc, dem has the trend of gradually replacing the barbiturates and benzodiazepine steeping.

The result of its widely used and easily obtained, the criminal cases showed a trend of rising.Zolpidem Phenyl-4-carboxylic acid is the rurinary metabolite of zolpidem, accounting for 51% of an administered dose. Literature references indicate the metabolite can und in urine after ingesting a single therapeutic dose of zolpidem, for 2-3 days. Only 1% deem was extracted with original version by urine. ²⁻¹³

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Zolpidem Phenyl-4-carboxylic acid in urine exceeds

Methicatininone (MCA1 1000)
Methicatininone, a methyl derivative of cathinone, is an illicit drug also known as ephedrone. It is a stimulant found in the "khat" plant, Catha edulis, which can easily be synthesized from pseudoephedrine. It is used as a recreational drug due to its potent stimulant and euphoric effects and is considered to be addictive, with both physical and psychological withdrawal occurring it its use is discontinued after prolonged or high-dosage administration. It is usually snorted, but can be smoked, injected, or taken orally. Effects of this drug typically las

prolonged or high-dosage administration. It is usually snorted, but can be smoked, injected, or taken orally. Effects of this arrug typically last from 4 to 6 hours.

Methicathinone is listed as a Schedule I controlled substance by the Convention on Psychotropic Substances and the United States' Controlled Substances Act, and as such it is not considered to be safe or effective in the treatment, diagnosis, prevention, or cure of any disease, and has no approved medical use. Possession and distribution of methicathinone for the purpose of human consumption is illegal under anyfall circumstances in the United States and is either illegal or highly regulated in most jurisdictions world-wide.

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Methicathinone in urine exceeds 1000ng/mL.

Mephedrone, also known as 4-methylmethcathinone(4-MMC) or 4-methylephedrone, is a synthetic stimulant drug of the amphetamine and cathinone classes. Slang names include bath salts, drone, M-CAT, White Magic and meow meow. It is chemically similar to the cathinone compounds found in the khat plant of eastern Africa.

Mephedrone has been used as a recreational drug in Europe and elsewhere in the world since 2007. It comes in the form of tablets or a

product, with users can swallow, snort or inject, producing similar effects to MDMA, amphetamines and cocaine. In addition to its stimulant effects, mephedrone produces side effects, of which teeth grinding are the most common. A number of metabolites are possible, however the n-demethyl metabolite of Mephedrone will be 4-Methylcathinone. This metabolite appears to be nearly inactive as a Monoamine Oxydase Inhibitor. On further metabolism of this metabolite one of the possible metabolites is 4-Methylnorephedrine, caused The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Mephedrone in urine exceeds 500ng/mL.

UR-144 5-Pentanoic acid metabolite, a primary urinary metabolite of UR-144, a synthetic cannabinoid found in many blends of the herbal mixture Spice also from the global drug market mixture Spice also from the global drug market

since the beginning of 2012.

(1-Pentyl-1H-indol-3-yl)(2,2,3,3-letramethylcyclopropyl)methanone (UR-144) is a synthetic cannabinoid receptor agonist (SCRA) that binds to and activates CB1 and CB2 receptors and the currently available data also suggest that UR-144 shows selectivity towards the CB2. receptor. Although there is an increasing indication that some SCRAs have been associated with dependence producing features, studie

receptor. Although there is an increasing indication that some SCRAs have been associated with dependence producing features, studies related to UR-144 specifically are not available.

Abuse potential: Clinical studies in humans could not be identified. Pharmacological investigations (in vitro and in vivo) confirmed that UR-144 shares similarities with 30-THC and other cannabinoid receptor agonists in its mechanisms of action, which was in alignment with the documented history of its use over several years since it emerged as a "research chemical" around 2012. Most commonly, this substance is encountered in the form of smokable 'herbal mixtures' although other forms have also been identified. The UR-144 Rapid Test is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal artibody to selectively detect elevated levels of UR-144 5-Pentanoic acid metabolite in urine.

The Multi-Drug Rapid Test Panel yields a positive result when UR-1445-Pentanoic acid metabolite in urine reaches 25 ng/mL. Lysergic acid diethylamide (LSDSO)

LSD (Lysergic acid diethylamide (LSDSO) which is one of the most effective hallucinogens, but non-addictive, is used mainly as an entheogen and recreational drug. LSD is very potent, with 20 - 30 µg being the threshold dose. After taking it 30 to 120 minutes, the effects are realized, which can normally last from 8 - 12 hours. However, acute adverse psychiatric reactions such as anxiety, paranoia,

effects are realized, which can normally last from 8 - 12 hours. However, acute adverse psychiatric reactions such as anxisting, paranola, and delusions are possible. The metabolize of LSD is very widely and rapidly, which taking 24 hours to discharge 90%, part of metabolism through the liver is 2-Cxx-3-hydroxy-LSD. ^{18,15,16}

The Multi-Drug Rapid Test Panel yields a positive result when the Lysergic acid diethylamide in urine exceeds 50ng/mL. FRINKING IS. a urine specimen migrates upward by capillary action. A drug, if present in the urine specimen below its cut-off

During testing, a urine specimen migrates upward by capillary action. A drug, if present in the urine specimen below its cur-ordination, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test region of the specific drug strip. The presence of drug above the cut-off concentration will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test region. A drug-positive urine specimen will not generate a colored line in the specific test region of the strip because of drug competition, while a drug-negative urine specimen will generate a line in the test region because of the absence of drug competition.

To serve as a procedural control, a colored line will always appear at the control region, indicating that proper volume of specimen has been added and mambrane wicking has concurred.

[REAGENTS] hered the test line contains anti-drug mouse monoclonal antibody and corresponding drug-protein conjugates. The control line contains goat li-rabbit IgG polyclonal antibodies and rabbit IgG.

professionals including professionals at point of care sites

For healthcare professionals including professionals at point of care sites.
 Immunoasay for invitro diagnostic use only. The test panel should remain in the sealed pouch until use.
 All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.
 The used test panel should be discarded according to federal, state and local regulations.
 ISTORAGE AND STABILITY]
 Store as packaged in the sealed pouch at 2-30°C. The test is stable through the expiration date printed on the sealed pouch. The test panels must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.

[SPECIMEN COLLECTION AND PREPARATION]

Urine Assay

The urine specimen should be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be centrifuged, filtered, or allowed to settle to obtain a clear specimen for testing.

Specimen Storage

Urine specimens may be stored at 2-8°C for up to 48 hours prior to testing. For prolonged storage, specimens may be frozen and stored below -20°C. Frozen specimens should be thawed and mixed well before testing.

[MATERIALS] Materials Provided

 Test Panels Package insert

Materials Required But Not Provided [DIRECTIONS FOR USE]

low the test panel, urine specimen, and/or controls to equilibrate to room temperature (15-30°C) prior to testing.

Bring the pouch to room temperature before opening it. Remove the test panel from the sealed pouch and use it within one hour. Remove the cap.

With the arrow pointing toward the urine specimen, immerse the test panel vertically in the urine specimen for at least 1016 ff. termove the cap. With the arrow pointing toward the urine specimen, immerse the test panel vertically in the urine specimen for at least 10 to 15 seconds. Immerse the strip to at least the level of the wavy lines, but not above the arrow on the test panel. Replace the cap and place the test panel on a non-absorbent little surface.

Start the timer and wait for the colored line(s) to appear. The result should be read at 5 minutes. Do not interpret the result after 10 min

Name Tal Faran Sant Maximum Line C C T C ŘĚŘĚŘ William II Multi-Drug Test Panel

[INTERPRETATION OF RESULTS]

(Please refer to the illustration above NEGATIVE: * Two lines appear. A colored line appears in the Control region (C) and a colored line appears in the Test region (T). This negative result means that the concentrations in the urine sample are below the designated cut-off levels for a particular drug tested.
*NOTE: The shade of the colored lines(s) in the Test region (T) may vary. The result should be considered negative whenever there is

even a faint line.

POSITIVE: A colored line appears in the Control region (C) and NO line appears in the Test region (T). The positive result means that the drug concentration in the urine sample is greater than the designated cut-off for a specific drug. INVALID: No line appears in the Control region (C). Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for Control line failure. Read the directions again and repeat the test with a new test panel. If the result is still invalid, contact your [QUALITY CONTROL]

ded in the test. A line appearing in the control region (C) is considered an internal procedural control. It confirms Control standards are not supplied with this kit. However, it is recommended that positive and negative controls be tested as good laboratory practice to confirm the test procedure and to verify proper test performance. laboratory practice to confirm the test procedure and to verify proper less performance.
 [LIMITATIONS]
 1. The Multi-Drug Rapid Test Panel provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. 1.10

There is a possibility that technical or procedural errors, as well as interfering substances in the urine specimen may cause erroneous

results.

Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.

A positive result does not indicate level or intoxication, administration route or concentration in urine.

A negative result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the

cut-off level of the test.

A positive test result may be obtained from certain foods or food supplements.

(PECTED VALUES) This test does not distinguish between drugs of abuse and certain medications

es that the drug concentration is below the detectable level. Positive result means the concentration of drug is

[PERFORMANCE CHARACTERISTICS]

A side-by-side comparison was conducted using the Multi-Drug Rapid Test Panel and commercially available drug rapid tests. Testing was performed on approximately 250 specimens per drug type previously collected from subjects presenting for Drug Screen Testing. Presumptive positive results were confirmed by GC/MS, LC/MS or LC-LC/MS

Method

GC/MS, LC/MS or LC-LC/MS

% agreement with GC/MS % agreement with GC/MS Negative Positive 97.0% AMP 1,000 98.1% 98.8% AMP 500 97.7% 99.4% AMP 300 Negative Positive 93.5% BAR 300 94.4% BAR 200 Negative 96.4% BZO 500 Negative 98.8% BZO 300 BZO 200 98.7% Negative 97.9% BZO 100 Negative 98.7% BUP 99.3% Negative COC 300 Negative 95.4% COC 150 Negative Positive >99.9% COC 100 93.2% THC 150 97.4% 97.8% THC 50 96.8% 99.2% THC 25 Negative Positive 99.2% THC 20 Negative 99.2% MTD 300 97.7% 99.2% MTD 200 97.7% Negative >99.9% 95.1% MET 1,000 >99.9% 96.7% MET 300 97.2% Negative 99.2% MDMA 1,000 >99.9% >99.9% MDMA 500 Negative 99.4% 96.9% MDMA 250 Negative 95.9% 96.9% MDMA 300 Positive 95.9% 99.3% MOP 300 97.6% MOP 100 97.0% MQL 98.7% OPI 2000 Positive >99.9% 93.5% >99.9% OPI 1000 93.5% >99.9% Positive PCP 99.5% Negative Positive 96.0% PPX Negative 98.0% TCA 99.0% TRA Negative 98.7% 94.4% 93.7% KET 1,000 Negative 96.6% KET 500 93.2% Negative Positive KET 300 Negative 91.8% OXY Negative Positive 143 99.3% COT 200 Negative 97.4% COT 100 Positive 95.8% 98.8% EDDP 300 EDDP 100 99.1% 92.9% 90.6% 96.9% K2-50 Negative 98.5% K2-30 Positive 97.8% ETG 500 Negative 99.1% 98.0% ZOL 99.2% Negative K2+(SMP) Negative Positive MCAT 1000 Negative MEP 500 Negative 96.0% UR-144

LSD		1 0311146			40				-				01.070		
50		Negative			4			2	218			99.1%			
The following res	ults were	abulated fror	n these cl								•				
						t with C									
	AMP 1,000	AMP 500	AMP 300	300		BAR 200		ZO 00	BZ 30		BZO 200	BZO 100	BUP	300	
Positive Agreement	>99.9%	>99.9%	>99.9%	>99.9	% >	99.9%	>99	9.9%	>99.	9%	>99.9%	>99.9%	>99.9%	>99.9%	
Negative Agreement	>99.9%	>99.9%	>99.9%	>99.9	% >	99.9%	>99	9.9%	>99.	9%	>99.9%	>99.9%	>99.9%	>99.9%	
Total Results	>99.9%	>99.9%	>99.9%	>99.9	% >	99.9%	>99	9.9%	>99.	9%	>99.9%	>99.9%	>99.9%	>99.9%	
	COC 150	100	THC 150		HC 50	TH 25			TD 00	M1 20		MET 1,000	MET 500	MET 300	
Positive Agreement	>99.9%	>99.9%	>99.9	% >9	9.9%	>99.	9%	>99	.9%	>99	.9%	99.9%	>99.9%	>99.9%	
Negative Agreement	>99.9%	>99.9%	>99.9	% >9	9.9%	>99.	9%	>99	.9%	>99	.9% >	99.9%	>99.9%	>99.9%	
Total Results	>99.9%	>99.9%	>99.9	% >9	9.9%	>99.	9%	>99	.9%	>99	.9% >	99.9%	>99.9%	>99.9%	
	MDMA	MDMA	MOF	, I	1OP						1	KET	KET	KET	
	1,000	500	300		100	MC)L	P	CP	PF	X	1,000	500	300	
Positive Agreement	>99.9%	>99.9%	>99.9	% >9	9.9%	>99.	9%	>99	.9%	>99	9% >	99.9%	>99.9%	>99.9%	
Negative Agreement	>99.9%	>99.9%	>99.9	% >9	9.9%	>99.	9%	>99	.9%	>99	9% >	99.9%	>99.9%	>99.9%	

Negative

Total Results	>99.9%	>99.9%	>99	.9%	>99.9%	>99.9%	>99.9%	>99.9%	6 >99.	9% :	>99.9%	>99.9%
	K2 50	K2 30	OPI 2000	OF 100		TRA	OXY	COT 200	COT 100	EDDF 300	P EDD 100	
Positive Agreement	*	*	*	*	*	*	*	*	*	*	*	*
Negative Agreement	*	*	*	*	*	*	*	*	*	*	*	*
Total Results	*	*	*	*	*		*	*	*	*	*	*

Total Results	*	*	*	,		*	*	*		*	*	,	*	*
	FYL	ETG	ZOL	K	2+	THO	MDM C	Α	MDMA	A UR	-144	MCAT	MEP	LSD
	10	500	50	(SMP) L	C-MS/N	IS 20	250		300	2	25	1000	500	50
Positive Agreement	*	*	*		*	*	*		*		*	*	*	*
Negative Agreement	*	*	*		*	*	*		*		*	*	*	*
Total Results	*	*	*		*	*	*		*		*	*	*	*
* Note:	Based on	GC/MS	or LC-MS				nmercial K MS, LC/M:		.C-MS	/MS				

Based on C	GC/MS or LO									
		% Agre								
AMP 1,000	AMP 500	AMP 300	BAR 300	BAR 200	BZO 500	BZO 300	BZO 200	BZO 100	BUP	COC 300
97.0%	98.8%	99.4%	93.5%	94.4%	96.4%	97.1%	97.2%	97.9%	99.0%	97.6%
98.1%	97.7%	98.6%	98.8%	98.7%	98.8%	98.8%	98.7%	98.7%	99.3%	95.4%
97.6%	98.2%	98.9%	96.3%	97.1%	97.7%	98.0%	98.0%	98.3%	99.2%	96.3%
COC 150	COC 100	THC 150	THC 50	THC 25	MTD 300	MTD 200	MET 1,000	MET 500	MET 300	MQL
99.1%	98.4%	97.7%	97.8%	99.2%	99.2%	98.1%	>99.9%	>99.9%	>99.9%	99.0%
99.1%		97.7% 97.4%	97.8% 96.8%	99.2% 95.5%	99.2% 97.7%	98.1% 97.9%	>99.9% 95.1%	>99.9% 96.7%	>99.9% 97.2%	99.0%
	AMP 1,000 97.0% 98.1% 97.6%	AMP 1,000 500 97.0% 98.8% 98.1% 97.7% 97.6% 98.2%	% Agre AMP AMP AMP 1,000 500 300 97.0% 98.8% 99.4% 98.1% 97.7% 98.6% 97.6% 98.2% 98.9% COC COC THC	% Agreement with AMP AMP BAR 1,000 500 300 300 97.0% 98.8% 99.4% 93.5% 98.1% 97.7% 98.6% 98.8% 97.6% 98.2% 98.9% 96.3% COC COC THC THC	% Agreement with GCMS, AMP AMP BAR BAR 1,000 500 300 300 200 97.0% 98.8% 99.4% 93.5% 94.4% 98.1% 97.7% 98.6% 98.8% 98.7% 97.6% 98.2% 98.9% 96.3% 97.1% COC COC THC THC THC	AMP AMP AMP BAR BAR BZO 500 500 97.0% 98.8% 99.4% 93.5% 94.4% 96.4% 98.1% 97.7% 98.6% 98.8% 98.7% 98.8% 97.6% 98.2% 98.9% 96.3% 97.1% 97.7% CCC CCC THC THC THC MTD	% Agreement with GCMS, LCMS or LC-MS/MS AMP AMP BAR BAR BZO BZO 1,000 500 300 300 200 500 300 97.0% 98.8% 99.4% 93.5% 94.4% 96.4% 97.1% 98.1% 97.7% 98.6% 98.8% 98.7% 98.8% 98.8% 97.6% 98.2% 98.9% 96.3% 97.1% 97.7% 98.0% COC COC THC THC THC MTD MTD MTD	% Agreement with GCMS, LCMS or LC-MSMS AMP AMP BAR BAR BAC BZO BZO 1,000 500 300 300 200 500 300 200 97.0% 98.8% 99.4% 93.5% 94.4% 96.4% 97.1% 97.2% 98.1% 97.7% 98.6% 98.8% 98.7% 98.8% 98.8% 98.8% 98.8% 98.8% 98.7% 97.6% 98.2% 98.9% 96.3% 97.1% 97.7% 98.0% 98.0% COC COC THC THC THC MTD MTD MET	% Agreement with GC/MS, LC/MS or LC-MS/MS AMP AMP BAR BAR BAC BZO B	% Agreement with GC/MS, LC/MS or LC-MS/MS AMP AMP BAR BAR BZO BZO BZO BZO BUP 1,000 500 300 300 200 500 300 200 100 BUP 97.0% 98.8% 99.4% 93.5% 94.4% 96.4% 97.1% 97.2% 97.9% 99.0% 98.1% 97.7% 98.6% 98.8% 98.7% 98.8% 98.8% 98.7% 98.8% 98.7% 98.3% 99.2% COC COC THC THC THC MTD MTD MET MET MET

rotal nesults	33.076	33.476	37.376	37.376	30.376	30.376	30.076	37.470	30.376	30.076	30.0
•											
	MDMA 1,000	MDMA 500	MOP 300	MOP 100	OPI 2000	PCP	KET 1,000	KET 500	KET 300	K2 50	K2 30
Positive Agreement	99.2%	>99.9%	99.3%	>99.9%	>99.9%	>99.9%	94.4%	96.6%	94.0%	96.9%	98.5%
Negative Agreement	>99.9%	99.4%	97.6%	97.0%	93.5%	99.5%	93.7%	93.2%	91.8%	98.7%	98.7%
Total Results	99.7%	99.7%	97.8%	98.4%	96.0%	99.7%	94.0%	94.8%	92.8%	98.3%	98.79
	PPX	TCA	TRA	OXY	COT 200	COT 100	EDDP 300	EDDP 100	FYL20	FYL10	500
Positive	96.0%	97.6%	99.0%	98.1%	94.6%	95.8%	98.8%	96.7%	99.1%	99.1%	97.89
Agreement	00.070	07.070	00.070	00.170	54.070	00.070	00.070	00.7 70	00.170	00.170	07.07
Agreement Negative Agreement	98.0%	93.3%	98.7%						92.9%	90.6%	99.19

A study was conducted at three hospitals by untrained operators using three different lots of product to demonstrate the within run, between run and between operator precision. An identical card of coded specimens, containing drugs at concentrations of ± 50% and ± 25% cut-off level, was labeled, blinded and tested at each site. The results are given below:

AMPHETAMINE (AMP 1,000)

Amphetical card of coded specimens, containing drugs at concentrations of ± 50% and ± 25% cut-off level, was labeled, blinded and tested at each site. The results are given below: care site. Based on GC/MS or LC-MS/MS data, the operator obtained statistically similar positive agreement, negative agreement an

K2+ THC MDMA MDMA MCAT MEP 20 250 300 1000 500

94.3% | 98.0% | >99% | 99.2% | 96.9% | 96.9% | >99.9% | >99.9% | 96.0% | 97.3%

91.3% 99.2% >99% 95.5% 95.9% 95.9% >99.9% >99.9% 98.0% 99.1%

Ampnetamine	n per	SIL	e A	Sit	ев	Sit	e C
conc. (ng/mL)	site	-	+		+		+
0	10	10	0	10	0	10	0
500	10	10	0	10	0	10	0
750	10	9	1	8	2	8	2
1,250	10	2	8	2	8	2	8
1,500	10	0	10	0	10	0	10
500)							
Amphetamine	n per	Sit	te A	Sit	е В	Sit	e C
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0
375	10	8	2	8	2	8	2
625	10	2	8	2	8	2	8
750	10	0	10	0	10	0	10
300)							
Amphetamine	n per	Sit	e A	Sit	e B	Site	e C
conc. (ng/mL)	site	-	+	-	+		+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
	conc. (ng/mL) 0 500 750 1,250 1,500 2,500 Amphetamine conc. (ng/mL) 0 2,50 375 625 750 Amphetamine conc. (ng/mL) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	conc. (ng/mL) site 0 10 500 10 750 10 1,250 10 1,500 10 200 10 Amphetamine conc. (ng/mL) site 0 10 250 10 375 10 625 10 750 10 300) Amphetamine conc. (ng/mL) site 0 10	conc. (ng/mL) site - 0 10 10 10 500 10 10 10 750 10 9 1,250 10 2 1,500 10 0 2 1,500 10 0 Amphetamine conc. (ng/mL) site - 0 10 10 10 10 25 10 250 10 10 10 10 25 10 25 10 2 75 10 8 625 10 2 75 300 10 10 0 10 <	conc. (ng/mL) site - + 0 10 10 0 500 10 10 0 750 10 9 1 1,250 10 2 8 1,500 10 0 10 20 10 10 10 370 10 10 10 250 10 10 10 0 375 10 8 2 625 10 2 8 2 750 10 0 10 10 3700) Amphetamine conc. (ng/mL) silte A conc. (ng/mL) Silte A conc. (ng/mL) 10 10 10 10	conc. (ng/mL) site - + - 0 10 10 0 10 500 10 10 0 10 750 10 9 1 8 1,250 10 2 8 2 1,500 10 0 10 0 Amphetamine conc. (ng/mL) site - + - 0 10 10 0 10 250 10 10 0 10 375 10 8 2 8 625 10 2 8 2 750 10 0 10 0 3700) Amphetamine conc. (ng/mL) silte - + - 0 10 10 0 10 0	conc. (ng/mL) site - + - + 0 10 10 0 10 0 500 10 10 0 10 0 750 10 9 1 8 2 8 1,550 10 2 8 2 8 2 8 1,550 10 0 10 0 10 0 10 500 10 10 0 10 0 10 0 10 500 10 10 0 10 0 10 0 0 10 0	conc. (ng/mL) site - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + -

	Ampnetamine	n per	Sit	e A	Siti	eв	Site	9 C
	conc. (ng/mL)	site		+		+	-	+
	0	10	10	0	10	0	10	0
	150	10	10	0	10	0	10	0
	225	10	7	3	8	2	8	2
	375	10	2	8	2	8	2	8
	450	10	0	10	0	10	0	10
BITURA	TES (BAR 300)							
	Secobarbital	n per	Sit	e A	Sit	e B	Site	e C
	conc. (ng/mL)	site		+		+		+
	0	10	10	0	10	0	10	0
	150	10	10	0	10	0	10	0
	225	10	9	1	8	2	8	2
	375	10	2	8	1	9	2	8

	450	10	0	10	0	10	0	10
JRAT	TES (BAR 200)							
	Secobarbital	n per	Sit	e A	Site	e B	Site	e C
	conc. (ng/mL)	site		+		+		+
	0	10	10	0	10	0	10	0
	100	10	10	0	10	0	10	0
	150	10	9	1	9	1	8	2
	250	10	2	8	1	9	1	9
	300	10	0	10	0	10	0	10
IAZE	PINES (BZO 500)							
	Oxazepam	n per	Sit	e A	Sit	e B	Site	e C
	conc. (ng/mL)	site		+		+	-	+
	0	10	10	0	10	0	10	0

	250	10	10	0	10	0	10	0
	375	10	8	2	9	1	9	1
	625	10	1	9	1	9	1	9
	750	10	0	10	0	10	0	10
BENZODIAZE	PINES (BZO 300)							
	Oxazepam	n per	5	Site A	Si	te B	Sit	e C
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	150	10	10	0	10	0	10	0
	225	10	9	1	9	1	9	1

10 1 9 1 9 1 9

	450	10	0	10	0	10	0	10
ZODIAZE	PINES (BZO 200)							
	Oxazepam	n per	Site	e A	Site	е В	Site	e C
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	100	10	10	0	10	0	10	0
	150	10	8	2	8	2	9	1
	250	10	1	9	1	9	1	9
	300	10	0	10	0	10	0	10
ZODIAZE	PINES (BZO 100)							

	300	10	0	10	0	10	0	10
BENZODIAZE	PINES (BZO 100)							
	Oxazepam	n per	Sit	e A	Sit	B	Sit	e C
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	50	10	10	0	10	0	10	0
	75	10	9	1	8	2	9	1
	125	10	1	9	1	9	2	8
	150	10	0	10	0	10	0	10
BUPRENORP	HINE (BUP)							
	Buprenorphine	n per	Sit	e A	Sit	e B	Sit	e C

	Buprenorpnine	n per	Sit	e A	310	6 D	5	60	
	conc. (ng/mL)	site	-	+	-	+	-	+	
	0	10	10	0	10	0	10	0	
	5	10	10	0	10	0	10	0	
	7.5	10	9	1	8	2	8	2	
	12.5	10	1	9	1	9	1	9	
	15	10	0	10	0	10	0	10	
NE (CC	DC 300)								
	Benzoylecgonine	n per	Sit	e A	Sit	e B	Sit	e C	

	Benzoylecgonine	n per	Sit	e A	Sit	е В	Sit	e C
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	150	10	10	0	10	0	10	0
	225	10	9	1	8	2	8	2
	375	10	1	9	1	9	1	9
	450	10	0	10	0	10	0	10
AINE (CO	DC 150)							
	Benzoylecgonine	n per	Sit	e A	Sit	e B	Sit	e C
	conc. (ng/mL)	site	,	+	,	+	,	+
			•	۰		۰	•	۰

COCAIN

	450	10	0	10	0	10	0	10
OCAINE (COC	150)							
	Benzoylecgonine	n per	Sit	e A	Sit	e B	Sit	e C
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	75	10	10	0	10	0	10	0
	112.5	10	8	2	8	2	8	2
	187.5	10	1	9	- 1	9	1	9
	225	10	0	10	0	10	0	10
CAINE (COC	100)	•		•	•	•		

1			10					_		
Mate	_	150								L
1	MARIJUANA (T	11-nor-Δ ⁹ -COOH		1 1	Site B	Site C		31.25	10	F
1		75	10	10 0	10 0	10 0	PROPOXYPH	Propoxyphene		L
The column	-	187.5	10	1 9	1 9	1 9		150	10	E
The column	MARIJUANA (T	11-nor-Δ ⁹ -COOH						375	10	F
The column		0 25	10	10 0 10 0	10 0 10 0	10 0	TRICYCLIC A	Nortriptyline		Ē
Mathematical		62.5	10	1 9	1 9	1 9		500	10	E
Part	MARIJUANA (T	11-nor-∆9-COOH						1,250 1,500	10	Ė
Part		12.5	10	10 0 10 0	10 0	10 0	Tramadol (TF			F
Part	_	31.25	10	1 9	1 9	2 8		50	10	E
Part	MARIJUANA (T	11-nor-∆9-COOH						125 150	10	
Mathematical Math		10	10	10 0	10 0	10 0	KETAMINE (I			_
Mathematical	_	25 30	10	2 8	1 9	2 8		500	10	E
1	METHADONE (Methadone			1			1,250 1,500	10	Ė
Mathematical		150	10	10 0	10 0	10 0	KETAMINE (I	•		F
Martinophi	-	375 450	10	1 9	1 9	1 9		250	10	F
Mathematical Math	METHADONE (Methadone					KETAMBIE (I	625 750	10	Ė
Mathematical		100	10	10 0	10 0	10 0	KETAMINE (I	Ketamine conc. (ng/mL)	site	E
STATE STAT	E	250 300	10	1 9	1 9	1 9		150	10	F
Mathematical Content	METHAMPHET	Methamphetamine					Ovycodone (450		E
1.500	_	500	10	10 0	10 0	10 0	Oxysodone (Oxycodone conc. (ng/mL)	site	E
Mathemplement	METHAMBHET	1,250 1,500	10	1 9	1 9	1 9		50	10	F
Mathematical Company	METHAMPHEL	Methamphetamine conc. (ng/mL)	site	- +	- +	- +	Cotinine (CO	150		E
Mathematical	_	250	10	10 0	10 0	10 0				E
Methylambigheiden Part		750						100	10	L
1	метнамрнет	Methamphetamine conc. (ng/mL)	site	- +	- +	- +		250	10	F
METHYLENEODOVERTRAINPHTAMINE (MOMA 500) Cut 1		150	10	10 0	10 0	10 0	COTININE (C	OT 100)	n per	F
Methylocationynethia	METHY! ENED!	450	10					50	10	Ė
State	METHYLENEDI	Methylenedioxymethamphetamine conc. (ng/mL)	n per site	- +	- +	- +		125	10	F
		500	10	10 0	10 0	10 0	2-ETHYLIDEI		n per	3 30
Methyleneticipyrethinipyrethinine per								150	10	E
Part	METHYLENEDI	Methylenedioxymethamphetamine	n per	Site A	+	Site C		375 450	10 10	Ė
375 10 2 8 1 9 1		0	10		10 0		2-ETHYLIDEI	EDDP conc. (ng/mL)	n per site	, 10
Methylamedicomymethylamine growth properties Sile A Sile B Sile C C C C C C C C C C						+		50	10	Ė
Conc. (right) Sile	METHYLENEDI	OXYMETHAMPHETAMINE (MDMA 25	50) Ecstasy				FENTANYL (150		E
18.75		conc. (ng/mL)	site 10	10 0	10 0	10 0	·		site	E
MethylenediogyNaterHammer Annie (MDMA 300) Estatey Sile A Sile B Sile C C C C C C C C C C		187.5 312.5	10 10	8 2 2 8	9 1 1 9	9 1 1 9		10 15	10 10	Ė
0	METHYLENEDI	OXYMETHAMPHETAMINE (MDMA 30 Methylenedioxymethamphetamine	00) Ecstasy				FENTANYL (30		L
MORPHINE (MOP 300)	_	0	10	10 0	10 0	10 0			site	F
Morphine Morphine Conc. (ng)mL)		375	10	2 8	9 1 1 9	9 1 1 9		7.5	10	E
O	MORPHINE (MC	DP 300) Morphine	n per	Site A	Site B	Site C	K2-50	15	10	Ļ
MORPHINE (MOP 100)		0 150	10 10	10 0 10 0	10 0 10 0	10 0 10 0		(ng/mL)	Site	F
Morphine n per Site A Site B Site C		375 450	10	1 9	1 9	1 9		37.5	10	F
Sile	MORPHINE (MC	Morphine					K2-30			İ
125		50	10	10 0	10 0	10 0		(ng/mL)	Site	F
Methaqualone site	MET.UA () UA ()	125 150	10	1 9	2 8	1 9		15 22.5	10 10	F
150	METHAQUALO	Methaqualone conc. (ng/mL)	site	- +	- +	- +	ETG-500			L
MORPHINE/OPIATE (OPI 1,000)	F	150	10	10 0	10 0	10 0		(ng/mL)	Site	F
Morphine n per Site A Site B Site C	MORPHINE	375 450	10	1 9	2 8	1 9		250	10	F
1,000 10 10 0 10 0 10 0 0	ORFRINE/OP	Morphine conc. (ng/mL)	site	- +	- +	- +	W6 (0110)	625	10	F
2,500 10 1 9	F	1,000	10	10 0	10 0	10 0	K2+(SMP)	Concentration (ng/mL)	Site	F
Morphine n per Site A Site B Site C 15 10 conc. (ng/mL) site - + - + - + - + - + - + - + - + - + -	MORPHINE/OP	2,500 3,000	10	1 9	1 9	1 9		5 7.5	10 10	F
	JIII IIIIVE/OP	Morphine conc. (ng/mL) 0	site 10	- + 10 0	- + 10 0	- + 10 0	ZOL-50	15	10 n per	I T
500 10 10 0 10 0 10 0 20 pidem Concentration (ng/mL) Site 750 10 9 1 9 1 8 2 1,250 10 1 9 1 9 1 9 10 25 10 10 25 10		500 750 1,250	10 10 10	10 0 9 1 1 9	10 0 9 1 1 9	10 0 8 2 1 9		0 25	10 10	E
PHENCYCLIDINE (PCP) 37.5 10 Phencyclidine n per Site A Site B Site C 75 10	PHENCYCLIDIN	NE (PCP) Phencyclidine	n per	Site A	Site B	Site C		62.5	10	Ė
conc. (ng/mL) site - + - + - + MCAT-1000		cont. (rig/IIIL)	sile	+	+	- +	MCAT-1000			

		1	1	ı	1		ı	ī	
	0 12.5	10	10 10	0	10	0	10 10	0	
	18.75 31.25	10 10	8	9	9	9	8	2 8	
PROPOXYPH	37.5 HENE (PPX)	10	0	10	0	10	0	10	
	Propoxyphene conc. (ng/mL)	n per site	-	e A +	-	e B +	-	e C +	MEP
	0 150	10	10	0	10	0	10	0	
	225 375	10	1	9	9	9	2	8	
TRICYCLIC A	450 ANTIDEPRESSANTS (TCA) Nortriptyline	10 n per	0 Sit	10 e A	0 Sit	10 e B	0 Sit	10 e C	
	conc. (ng/mL)	site	- 10	+ 0	- 10	+	- 10	+ 0	UR-1
	500 750	10 10	10	0	10	0	10	0	
	1,250 1,500	10 10	1	9	1	9	2	8 10	
Tramadol (Ti	Tramadol conc. (ng/mL)	n per	Sit	e A	Site		Sit		
	0	site 10	10	0	10	0	10	0	100
	50 75	10	9	1	10	2	8	2	LSD
KETAMINE (I	125 150 KET1 000)	10	0	9 10	0	9 10	0	10	
KETAMINE (Ketamine conc. (ng/mL)	n per site	Sit	e A +	Sit	e B +	Sit	e C +	
	0 500	10 10	10	0	10	0	10 10	0	
	750 1,250	10 10	9	1 9	8	9	9	1 8	A dru
KETAMINE (1,500 KET500)	10	0	10	0	10	0	10	
	Ketamine conc. (ng/mL)	n per site	- Sit	e A + 0	- 10	e B + 0	- 10	e C + 0	
	250 375	10 10 10	10 10 9	0 0	10 10 9	0 0	10 10 8	0 0 2	
	625 750	10	1 0	9	1 0	9	2	8	
KETAMINE (KET300)	n per		e A		e B		e C	L
	Ketamine conc. (ng/mL)	site 10	10	+	10	+	10	+ 0	Drug
	150 225	10	10	0	10	0	10	0	H
	375 450	10 10	0	9 10	0	9 10	0	10	
Oxycodone (Oxycodone conc. (ng/mL)	n per site	Sit	e A +	Sit	e B +	Sit	te C	
	0 50	10	10	0	10	0	10	0	
	75 125	10 10	9	1 9	9	1 9	9	1 8	
Cotinine (CO	150 T 200)	10	0	10	0	10	0	10	
	Cotinine conc. (ng/mL)	n per site	Sit	+	Site	+	Site	+	
	0 100	10 10	10	0	10	0	10	0	
	150 250	10 10	9	9	9	9	9	1 8	
COTININE (C	300	10	0	10	0	10	0	10	
·	Cotinine conc. (ng/mL)	n per site	Site	e A +	Site	∌ B +	Site	e C +	
	0 50	10 10	10 10	0	10 10	0	10 10	0	
	75 125	10 10	9	9	9	9	9	8	
2-ETHYLIDE	150 NE-1,5-DIMETHYL-3,3-DIPHENYLPYRROL		0 300) Site	10	0 Site	10	0 Site	10	
	EDDP conc. (ng/mL)	n per site 10	- 10	+ 0	- 10	+ 0	- 10	+ 0	_
	150 225	10	10	0	10	0	10	0	
	375 450	10 10	1	9	2	8 10	1	9	
2-ETHYLIDE	NE-1,5-DIMETHYL-3,3-DIPHENYLPYRROL EDDP conc. (ng/mL)	n per site	Sit	e A	Sit	е В		e C	
	0 50	10 10	10	0	10	0	- 10 10	0	
	75 125	10	8	2	9	1 9	9	1 9	L
FENTANYL (150	10	0	10	0	10	0	10	D
	Norfentanyl conc. (ng/mL)	n per site	-	e A +	Sit	+	-	e C +	
	10	10	10	0	10	0	10	0	
	15 25 30	10 10 10	8 1 0	9 10	9 1 0	9 10	9 2 0	1 8 10	
FENTANYL (FYL10)	n per		e A	Sit			e C	
	Norfentanyl conc. (ng/mL)	site 10	- 10	+ 0	- 10	+ 0	- 10	+ 0	D
	5 7.5	10 10	10 8	2	10 9	1	10 9	0	
	12.5 15	10 10	0	9 10	0	9 10	0	10	
K2-50	Synthetic Marijuana Concentration (ng/mL)	nper Site	Sit	e A	Sit	e B	Sit	e C	
	0 25	10	10	0	10	0	10	0	Щ
	37.5	10	8	2	9	1	9	1	The fat 5 i
K2-30	62.5 75	10	0	9 10	0	9 10	0	10	
K2-30	Synthetic Marijuana Concentration (ng/mL)	nper Site	Sit	e A +	Sit	e B +	Site	e C +	
	0	10	10	0	10	0	10	0	
	22.5 37.5	10	8	2	9	1 9	9	1 8	
ETG-500	45	10	0	10	0	10	0	10	
	Synthetic Marijuana Concentration (ng/mL)	nper Site	Sit	e A +	Sit	e B +	Sit	e C +	
	0 250	10 10	10	0	10	0	10	0	
	375 625	10	6	4 8	7	3	6	4 9	
K2+(SMP)	750	10	0	10	0	10	0	10	
	AB-PINACA metabolite	nper	Sit	e A	Sit	e B	Site	e C	

	Methca	thinone	Conc	entra	tion (ng/ml	.)	n per Site			Site	A +	-	Site B	+	- 1	Site C	+		
			500)			#	10		_	0	0	10		0	10	‡	0		
			750 125)			+	10 10		_	0 7 I	0 3 9	10 7 1		0 3 9	10 8 2	+	2		
MEP-500			150	-			_	10		-)	10	0		10	0	<u> </u>	10		
	Mephe	edrone	Conce	ntrati	on (n	g/mL)		n pei Site			Site	A +	-	Site B	+	-	Site C	+		
			500				#	10			0	0	10	_	0	10	‡	0		
			750 125				_	10			7	3	7		3	8	+	2		
JR-144 -25			150	0				10)	10	0		10	0	1	10		
	UR-144	4 5-Per Conce				abolite		n per Site			Site	A +	-	Site B	+	-	Site (+		
			12.5	5			7	10		_	0	0	10	1	0	10	+	0		
			18.7	5			\dashv	10			9	1	8	ļ	2	9	+	1 9		
.SD-50			37.5					10		_)	10	0		10	0	1	10		
		Conce			/mL)			nper Site			Site	+	-		+	-	Site C	+		
			0 25				$\frac{1}{2}$	10		-)	10	0		10	0	\downarrow	10		
			37. 62.				1	10 10		!	1	1	9		1	9	ŧ	1		
A drug-free u	rine nool wa	is snike	75 ad with	dnia	s at ti	he list		10 alytica		ensit		0 ults are	10		0 I belov	10		0		
Drug Conc	entration	AN 1,0	IP	AN 50	ИP	-	AMP 300	E	300			λR	BZ 50	0	BZ 30	O.		BZO 200		BZO 100
Cut-off I		30	0	30	0	30	0	30	+	+ 0	30	0	30	0	30	0	30	+	30	,
-50% C		30 27	0	30 26	0	30 27	_	30 27	_	0	30 26	0	30 27	0	30 27	0	30 27	_	27	+
Cut-	off	14	16	15	15	15	15	16	1	14	15	15	15	15	14	16	14	16	15	
+25% C +50% C	ut-off	0	30	0	30	0	30	0	3	26 30	0	30	0	26 30	0	27 30	0	30	0	:
+300%	Cut-off	0	30	0	30	0	30		3	30	0	30	0	30	0	30	0	30		ATD.
Orug Concer Ra	tration Cut-	off -	BUP	+	30 -			150 +	+)O)O +		HC 150 +	+-	THC 50	+	- TF	HC 5 +		MTD 300
	Cut-off Cut-off	30) ()	30 30	0	30	0	_	30 30	0	30 30	0	30) ()	30 30	0	30 30	Ŧ
	Cut-off t-off	26	_	_	26 15	4 15	27 15	_	_	27 16	3 14	27 15	3 15	26	_	_	27 14	3 16	27 15	-
+25%	Cut-off Cut-off	3	. 2	_	3	27 30	3	27 30	Ţ	4 0	26 30	4	26 30	3	3	7	3	27 30	3	3
+300%	Cut-off	0		0	0	30	0	30		0	30	0	30	0	3	0	0 MC	30	0	OP.
	centration Range		1TD 200 +		MET 1,000	+	ME1 500			00		MDI 1,0			IDMA 500 +	+	MO 30			OP 00
	Cut-off	30 30	0	30	_	_	30 30	_	30 30	-)	30 30	0	30 30	0	_	30 30	0	30 30	(
	Cut-off	26 14	4 16	26	_	_	25 15	_	25 15	-	5	26 15	4 15	25 14	5 16	_	25 15	5 15	27 16	1
	Cut-off Cut-off	3	27 30	3	_	27	_	26 30	4 0	-	6	5	25 30	4	30	_	3	27 30	4	3
	Cut-off	0	30	0	:	30	_	30	0	3	0	0	30	0	30	_	0	30	0	3
	centration Range		OPI 2000 +	+	PCI	+	-	PX +	-	тс -	A +	- T	RA +		,000 +	+	50 -			ET 00 +
	Cut-off	30	0	3	_	0	30	0	3	$\overline{}$	0	30	0	30	0	_	30 30	0	30	(
-25%	Cut-off	27 15	3	2	_	4	27 14	3 16	2	$\overline{}$	5	27	3 16	26 16	14	:	27 15	3	26 14	1
+25%	Cut-off	4	26		_	27	4	26 30	3	$\overline{}$	27 30	4	26	4	26	3	3	27	4	3
	Cut-off	0	30	()	30	0	30	(30	0	30	0	30)	0	30	0	3
	centration Range	-	/QL	+	OX'	Y +		OT 00 +	ļ.	10 -			DP 00 +		DDP 100 +	+	FY 20			YL 10
	Cut-off	30	0	3	_	0	30 30	0	3	_	0	30	0	30	0	_	30 30	0	30 30	(
-25%	Cut-off	27	3	2	7	3	27 15	3	2	$\overline{}$	3	27 16	3	27 16	3	-	27 16	3	27 16	1
+25%	Cut-off Cut-off	3	27	. 4		26 30	4	26 30	(4	26 30	4	26 30	4	30	3	3	27 30	3	3
	Cut-off	0	30	(30	0	30	(30	0	30	0	30)	0	30	0	3
Drug Cond Cut-off			K2 50 +	-	K2 30	+	50 -		-	K2- (SM)		Z0 5			OPI 000 +	+	THO 20	+	MD 25	
0% C		30 30	0	30	_	0	20 20	0	30		0	30 30	0	30 30	0	_	10	0	30 30	0
-25% (Cut-off	27 16	3	27	7	3	18 12	2	27 15	_	3 15	27 15	3 15	27 15	3 15	2	3	3	25 14	5
+25% (Cut-off	3	27 30	3	1	27 30	3	17 20	3		27 30	4 0	26 30	4	26	Ţ.	4	26 30	4	26
+300%		0	30	0	1	30	0	20	0		30	0	30	0	30	_	0	30	0	30
Drug Con Cut-off			OMA 800 +	+	MCA 1000			EP 00 +		UR-1 25 -			SD 50 +							
0% C		30	0	31	_	0	30	0	3	_	0	30	0							
-25% (Cut-off	25 14	5	2	7	3	27 14	3	1	9	11	27 15	3							
+25% (Cut-off	4	26	4		26	0	26 30	0)	30	4	26							
+300%		0	30	0		30	0	30	C)	30	0	30	1						
he following at 5 minutes.	table lists th	ne cond	entrat	ions c	of con		ds (ng					d as p	ositive	in urin					pid Te	st Pa
	Analytes					(ng/	centra mL)	ation ETAMI			ytes P 1.00	00)				oncei g/mL	ntrati .)	on		
	D,L-Amph	amine		ate		200		1 AM	P	hen ⁄apr	termir otiline	ne				,000				
	(±) 3,4-Me amphetam		edioxy			400	AMP	HETAN	C)-An	pheta		ne			000				
	D,L-Amph L-Amphet	amine				100 12,5		All	P	hen //apr	termir otiline	ne				5,000				
	(±) 3,4-Me amphetam	ethylene nine	edioxy			200	ДМР	HETAN	N D	/leth)-An	oxyph pheta	enamir amine	ne			000				
	D,L-Amph		e sulfa	ate		70 10,0		I AIV	P	hen //apr	termir otiline	ne				2,500				
	(±) 3,4-Me amphetam	ethylene	edioxy			150			N D	∕leth)-An	oxyph opheta	enamir amine	ne		2,	000				

Analytes	Concentration (ng/mL)	Analytes	Concentration (ng/mL)
-		NE (AMP 1.000)	(ng/mc)
D.L-Amphetamine sulfate	200	Phentermine	800
L-Amphetamine	25.000	Maprotiline	50,000
(±) 3.4-Methylenedioxy		Methoxyphenamine	6,000
amphetamine	400	D-Amphetamine	1,000
	ΔΜΡΗΕΤΔΜ	INE (AMP 500)	1,000
D.L-Amphetamine sulfate	100	Phentermine	400
L-Amphetamine	12.500	Maprotiline	25.000
(±) 3.4-Methylenedioxy		Methoxyphenamine	3,000
amphetamine	200	D-Amphetamine	500
	ΔΜΡΗΕΤΔΜ	INE (AMP 300)	
D.L-Amphetamine sulfate	70	Phentermine	300
L-Amphetamine	10.000	Maprotiline	12.500
(±) 3,4-Methylenedioxy		Methoxyphenamine	2.000
amphetamine	150	D-Amphetamine	300
,	BARBITURA	TES (BAR 300)	
Amobarbital	3,000	Alphenol	300
5,5-Diphenylhydantoin	6.000	Aprobarbital	450
Allobarbital	450	Butabarbital	150
Barbital	6.000	Butalbital	6.000
Talbutal	30	Butethal	450
Cyclopentobarbital	25,000	Phenobarbital	300
Pentobarbital	6,000	Secobarbital	300
	BARBITURA	TES (BAR 200)	
Amobarbital	2,000	Alphenol	200
5,5-Diphenylhydantoin	4,000	Aprobarbital	300
Allobarbital	300	Butabarbital	100
Barbital	4,000	Butalbital	4,000
Talbutal	20	Butethal	300
Cyclopentobarbital	17,000	Phenobarbital	200
Pentobarbital	4,000	Secobarbital	200
	BENZODIAZE	PINES (BZO 500)	
Alprazolam	200	Bromazepam	1,300
a-hydroxyalprazolam	2,500	Chlordiazepoxide	1,300
Clobazam	300	Nitrazepam	300
Clonazepam	650	Norchlordiazepoxide	200
Clorazepate dipotassium	650	Nordiazepam	1,300

Desalkylflurazepam	1,300 300	Oxazepam Temazepam	500 200 2 500
Flunitrazepam ±) Lorazepam RS-Lorazepam glucuronide	300 5,000 300	Diazepam Estazolam Triazolam	2,500 10,500 5,000
Midazolam	10,500 BENZODIAZEPI	NES (BZO 300)	
Alprazolam a-hydroxyalprazolam	100 1,500	Bromazepam Chlordiazepoxide	780 780
Clobazam Clonazepam	200 390	Nitrazepam Norchlordiazepoxide	200 100
Clorazepate dipotassium Delorazepam Desalkylflurazepam	780 200	Nordiazepam Oxazepam Temazepam	780 300 100
Flunitrazepam (±) Lorazepam	200 3,100	Diazepam Estazolam	1,500 6,250
RS-Lorazepam glucuronide Midazolam	200 6,250	Triazolam	3,100
Alprazolam	70 1,000	NES (BZO 200) Bromazepam Chlordiazepoxide	520 520
a-hydroxyalprazolam Clobazam Clonazepam	120	Nitrazepam Norchlordiazepoxide	120 70
Clorazepate dipotassium Delorazepam	260 520	Nordiazepam Oxazepam	520 200
Desalkylflurazepam Flunitrazepam	120 120	Temazepam Diazepam	70 1,000
±) Lorazepam RS-Lorazepam glucuronide	2,000 120 4,200	Estazolam Triazolam	4,200 2,000
Midazolam Alprazolam	BENZODIAZEPII	NES (BZO 100) Bromazepam	260
a-hydroxyalprazolam Clobazam	500 60	Chlordiazepoxide Nitrazepam	260 60
Clonazepam Clorazepate dipotassium	130 130	Norchlordiazepoxide Nordiazepam	40 260
Delorazepam Desalkylflurazepam	260 60	Oxazepam Temazepam	100 40
Flunitrazepam ±) Lorazepam RS-Lorazepam glucuronide	60 1,000 60	Diazepam Estazolam Triazolam	500 2,100 1,000
Midazolam	2,100 BUPRENORP		1,000
Buprenorphine Buprenorphine 3-D-Glucuronide	10 50	Norbuprenorphine Norbuprenorphine	50 100
	COCAINE (3-D-Glucuronide COC 300)	10.500
Benzoylecgonine Cocaine HCI	200 COCAINE (Cocaethylene Ecgonine COC 150)	12,500 30,000
Benzoylecgonine Cocaine HCI	150 100	COC 150) Cocaethylene Ecgonine	6,250 15,000
Benzoylecgonine	COCAINE (5, 000
Cocaine HCI	80 MARIJUANA	Ecgonine (THC150)	10,000
Cannabinol 11-nor-△8-THC-9 COOH	50,000 90	∆8-THC △9-THC	45,000 45,000
I1-nor-△9-THC-9 COOH	MARIJUAN		
Cannabinol 11-nor-△8-THC-9 COOH 11-nor-△9-THC-9 COOH	20,000 30 50	△8-THC △9-THC	15,000 15,000
I1-nor-△9-THC-9 COOH Cannabinol	50 MARIJUAN 10,000	A (THC25) I∆8-THC	7,500
11-nor-△8-THC-9 COOH 11-nor-△9-THC-9 COOH	15 25	△9-THC	7,500
Cannabinol	MARIJUAN 10,000	A (THC20) △8-THC	7,500
I1-nor-△8-THC-9 COOH I1-nor-△9-THC-9 COOH	15 20	△9-THC	7,500
Methadone	300	Doxylamine	100,000
Methadone	200 METHAMPHETAN	Doxylamine	60,000
o-Hydroxymethamphetamine O-Methamphetamine	25,000 1,000	(±)-3,4-Methylenedioxy- methamphetamine	6,250
-Methamphetamine	12,500 METHAMPHETA	Mephentermine MINE (MET500)	50,000
o-Hydroxymethamphetamine O-Methamphetamine	12,500 500	(±)-3,4-Methylenedioxy- methamphetamine	3,000
-Methamphetamine	9,000 METHAMPHETA 7,500	Mephentermine MINE (MET300) (±)-3,4-Methylenedioxy-	25,000
p-Hydroxymethamphetamine D-Methamphetamine Methamphetamine	300 3,750	(±)-3,4-Metnylenedioxy- methamphetamine Mephentermine	1,800
	DIOXYMETHAMPHE	TAMINE (MDMA1, 000) Ecstasy	1,000
3,4-Methylenedioxyethyl-ampheta ±) 3,4-Methylenedioxyamphetami	mine ne HCl		600 6,000
±) 3,4-Methylenedioxymethamphe	etamine HCI	ETAMINE (MDMA500) Ecstasy	500
3,4-Methylenedioxyethyl-amphetan ±) 3,4-Methylenedioxyamphetami	ne HCI	ETAMINE (MDMA250) Ecstasy	300 3,000
(±) 3,4-Methylenedioxymethamphe 3,4-Methylenedioxyethyl-ampheta	etamine HCI	ETAMINE (MDMA250) EGGESY	250 150
±) 3,4-Methylenedioxyamphetami			
METHYLENE		ETAMINE (MDMA300) Ecstasy	1,500
METHYLENE ±) 3,4-Methylenedioxymethampheta 3,4-Methylenedioxyethyl-ampheta	etamine HCI mine	ETAMINE (MDMA300) Ecstasy	300 180
±) 3,4-Methylenedioxymethamphe 3,4-Methylenedioxyethyl-ampheta ±) 3,4-Methylenedioxyamphetami	etamine HCI mine ne HCI MORPHINE	(MOP 300)	1,500 300 180 1,800
<u>METHYLENE</u> <u>3</u> , 3,4-Methylenedioxymethamphet <u>3</u> , 4-Methylenedioxyethyl-amphetami <u>3</u> , 3,4-Methylenedioxyamphetami Codeine Levorphanol	etamine HCI mine ne HCI MORPHINE 200 1,500	(MOP 300) Norcodeine Normorphone	1,500 300 180 1,800 6,000 50,000
METHYLENE ±) 3,4-Methylenedioxymethamphe 3,4-Methylenedioxyethyl-amphetan ±) 3,4-Methylenedioxyamphetami Codeine	etamine HCI mine HCI MORPHINE 200 1,500 800 6,000 50,000	(MOP 300) Norcodeine	1,500 300 180 1,800 6,000 50,000 30,000 50,000 15,000
METHYLENE ±) 3,4-Methylenedioxymethamphe \$,4-Methylenedioxyethyl-amphetami ±) 3,4-Methylenedioxyamphetami Codeine _evorphanol Morphine-3-β-D-Glucuronide Ethylmorphine	etamine HCI mine ne HCI MORPHINE 200 1,500 800 6,000 50,000 4,000 400	(MOP 300) Norcodeline Normorphone Oxycodone Oxymorphone Procaine Thebaine Morphine	300 180 180 1,800 6,000 50,000 30,000 50,000
METHYLENE ±) 3,4-Methylenedioxymethamphe 4),4-Methylenedioxyethyl-amphetati ±) 3,4-Methylenedioxyamphetami Codeine evorphanol dorphine-3-β-D-Glucuronide Ethylmorphine Hydrocodone Hydrocodone Hydromorphone 5-Monoacethylmorphine	stamine HCI mine ne HCI MORPHINE 200 1,500 800 6,000 50,000 3,000 400 MORPHINE	(MOP 300) Norcodeline Normorphone Oxycodone Oxymorphone Procaine Thebaine Morphine (MOP 100) Norcodeline	1,500 300 180 1,800 5,000 50,000 15,000 50,000 15,000 50,000 15,000 3000 2,000
METHYLENE ±) 3,4-Methylenedioxymethamphe ,3,4-Methylenedioxyethyl-amphetati ±) 3,4-Methylenedioxyamphetami Codeine .evorphanol Morphine-3-B-D-Glucuronide Ethylmorphine Hydrocodone Hydromorphone S-Monoacethylmorphine Codeine .evorphanol Morphine-3-B-D-Glucuronide	tatamine HCI mine ne HCI MORPHINE 200 11,500 800 6,6000 50,000 3,000 400 MORPHINE 80 500 3000	(MOP 300) Norcodeline Normorphone Oxycodone Oxymorphone Procaine Thebaine Morphine (MOP 100) Norcodeline Normorphone Oxycodone	1,500 300 180 1,800 6,000 50,000 30,000 50,000 15,000 6,000 2,000 2,000 2,000 10,000
METHYLENE ±) 3,4-Methylenedioxymethamphe ,3,4-Methylenedioxyaethyl-amphetat ±) 3,4-Methylenedioxyamphetami Codeine .evorphanol dorphine-3-β-D-Glucuronide Ethylmorphine Hydrocodone Hydromorphone S-Monoacethylmorphine Codeine .evorphanol dorphine-3-β-D-Glucuronide Ethylmorphine Codeine .evorphanol dorphine-3-β-D-Glucuronide Ethylmorphine Hydrocodone Hydrocodone Hydrocodone	tamine HCI mine ne HCI MORPHINE 200 1,500 800 6,000 50,000 80,000 MORPHINE 80 20,000 20,000 20,000	(MOP 300) Norcodeine Normorphone Oxycodone Oxymorphone Procaine Thebaine Morphine (MOP 100) Norcodeine Normorphone	1,500 300 180 1,800 5,000 5,000 30,000 5,000 15,000 2,000 2,000 2,000 1,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000
METHYLENE ±) 3,4-Methylenedioxymethamphe ,3,4-Methylenedioxyamphetami ±) 3,4-Methylenedioxyamphetami Codeine evorphanol Morphine-3-β-D-Glucuronide Ethylmorphine +ydromorphone -Honoacethylmorphine Codeine everphanol Morphine-3-β-D-Glucuronide Ethylmorphine -Honoacethylmorphine Codeine everphanol Morphine-3-β-D-Glucuronide Ethylmorphine -Honoacethylmorphine -Honoacethylmorphine	tamine HCI mine ne HCI MORPHINE 200 1,500 6,000 6,000 6,000 MORPHINE 80 500 MORPHINE 80 200 2,000 2,000 1,000 1,000 1,000 1,000 1,000 Methaqualon	(MOP 300) Norcodeline Normorphone Oxycodone Oxymorphone Procaline Thebaine Morphine (MOP 100) Norcodeline Normorphone Oxycodone Oxycodone Oxymorphone Procaline Thebaine Morphine	1,500 300 180 1,800 6,000 50,000 30,000 50,000 15,000 8,000 2,000 20,000 10,000 20,000 10,000 20,000
METHYLENE ±) 3,4-Methylenedioxymethamphe ,3,4-Methylenedioxyamphetami ±) 3,4-Methylenedioxyamphetami 2) 3,4-Methylenedioxyamphetami 20deine _everphanol Morphine-3-β-D-Glucuronide Ethylmorphine +ydrocodone +ydromorphone 5-Monoacethylmorphine 20deine _everphanol Morphine-3-β-D-Glucuronide Ethylmorphine +ydrocodone +ydromorphone 5-Monoacethylmorphine 5-Monoacethylmorphine -ydrocodone +ydromorphone 5-Monoacethylmorphine Mothylmorphine -Monoacethylmorphine Methaqualone	tatamine HCI mine ne HCI MORPHINE 200 1,500 800 6,000 5,000 3,000 400 MORPHINE 200 1,000 1,000 1,000 1,000 1,000 1,000 MORPHINE 300 MORPHINE 300 MORPHINE	(MOP 300) Norcodeine Normorphone Oxycodone Oxycodone Oxymorphone Procaine Thebaine Morphine (MOP 100) Norcodeine Normorphone Oxycodone Oxycodone Oxymorphone Procaine Thebaine Morphine e (MOL 300) LTE (OPI 2,000)	1,500 300 180 1,800 6,000 5,000 30,000 15,000 15,000 2,000 2,000 10,000 2,000 5,000 1,000 2,000
METHYLENE ±) 3,4-Methylenedioxymethamphe 4),4-Methylenedioxyamphetami 2) 3,4-Methylenedioxyamphetami 2) 3,4-Methylenedioxyamphetami 2) 3,4-Methylenedioxyamphetami 20deine 2-worphanol 3-B-D-Glucuronide 2-thylmorphine 4-ydrocodone 4-ydromorphone 3-Monoacethylmorphine 2-dedeine 2-worphanol 3-Morphine-3-β-D-Glucuronide 2-thylmorphine 4-ydrocodone 4-ydrocodone 4-ydrocodone 4-ydromorphone 5-Monoacethylmorphine 4-dedeine	tatamine HCI mine ne HCI MORPHINE 200 1,500 800 6,000 50,000 400 MORPHINE 80 500 20,000 1,000 1,000 MORPHINE 300 MORPHINE 300 MORPHINE 2,000 MORPHINE 300 MORPHINE 2,000 MORPHINE 300 MORPHINE 2,000 MORPHINE 300 MORPHINE 2,000 MORPHI	(MOP 300) Norcodeline Normorphone Oxycodone Oxymorphone Procaline Thebaine Morphine (MOP 100) Norcodeline Normorphone Oxycodone Oxycodone Oxymorphone Procaline Thebaine Morphine (MOP 300) Wigney Wig	1,500 300 180 1,800 1,800 6,000 50,000 30,000 15,000 15,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000
METHYLENE ±) 3.4-Methylenedioxymethamphe 5,4-Methylenedioxyethyl-amphetat ±) 3.4-Methylenedioxyamphetami Dodeine _evorphanol Morphine-3-B-D-Glucuronide Ethylmorphine +ydrocodone +ydromorphone Codeine _evorphanol Morphine-3-B-D-Glucuronide Ethylmorphine Dodeine _evorphanol Morphine-3-B-D-Glucuronide Ethylmorphine -Monoacethylmorphine -Monoacethylmorphine -Monoacethylmorphine -Monoacethylmorphine -Monoacethylmorphine -Monoacethylmorphine -Monoacethylmorphine -Monoacethylmorphine -Monoacethylmorphine -Methaqualone Dodeine Ethylmorphine -Jydrocodone -tydrocodone -tydrocodone -tydrocodone -tydrocodone -tydrocodone -tydromorphine	tatamine HCI mine ne HCI MORPHINE 200 1,500 800 6,000 50,000 400 MORPHINE 80 2,000 2,000 1,000 1,000 MORPHINE 300 MORPHINE 300 MORPHINE 300 2,000 1,000 1,000 MORPHINE 300 MORPHINE 300 300 300 300 MORPHINE 300	(MOP 300) Norcodeline Normorphone Oxycodone Oxymorphone Procaline Thebaline Morphine (MOP 100) Norcodeline Normorphone Oxycodone Oxycodone Oxymorphone Procaline Thebaline Morphine (MOP 100) Normorphone Oxymorphone Oxymorphone Oxymorphone Intelatine Morphine (MOL 300) ITE (OPI 2,000) Morphine Norcodeline Normorphone Oxycodone	1,500 300 180 1,800 180 1,800 5,000 30,000 30,000 50,000 15,000 20,000 10,000 20,000 10,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000
METHYLENE ±) 3,4-Methylenedioxymethamphe 3,4-Methylenedioxyamphetami ±) 3,4-Methylenedioxyamphetami Codeine -evorphanol Morphine-3-β-D-Glucuronide Ethylmorphine +ydromorphone -decorphanol Morphine-3-β-D-Glucuronide Ethylmorphine -ydromorphone -decorphanol Morphine-3-β-D-Glucuronide Ethylmorphine -decorphanol Morphine-3-β-D-Glucuronide -thydromorphone -decorphanol Morphine-3-β-D-Glucuronide -dethylmorphine	tamine HCI mine ne HCI MORPHINE 200 1,500 800 6,000 10,000 800 10,000 100 MORPHINE 100 Mothadalon 100 Mothadalon 100 100 MOTHADALON 100 100 MOTHADALON 100 100 100 100 100 100 100 100 100 10	(MOP 300) Norcodeline Normorphone Oxycodone Oxymorphone Procaline Thebaine Morphine (MOP 100) Norcodeline Normorphone Oxycodone Oxycodone Oxymorphone Procaline Thebaine Morphine Morphine Morphine Normorphone Oxymorphone Normorphone Oxymorphone Procaline Thebaine Morphine Normorphone Oxymorphone Oxymorphone Oxymorphone Procaline Thebaine Normorphone Oxymorphone Oxymorphone Oxymorphone Oxymorphone Oxymorphone Oxymorphone Oxymorphone Oxymorphone	1,500 1,50
METHYLENE ±) 3.4-Methylenedioxyethyl-ampheta ±) 3.4-Methylenedioxyethyl-ampheta ±) 3.4-Methylenedioxyathyl-ampheta ±) 3.4-Methylenedioxyamphetami Dodeine _evorphanol dorphine-3-B-D-Glucuronide Ethylmorphine -tydrocodone -tydromorphone -tydrocodone -tydromorphone -tydrocodone -tydrocodone -tydromorphone -tydrocodone -tydromorphone -tydrocodone -tydrocodone -tydromorphone -tyd	tatamine HCI mine ne HCI MORPHINE 200 1,500 800 6,000 50,000 30,000 400 MORPHINE 300 2,000 1,000 100 Methaqualon 300 MORPHINE 2000 3,000 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500	(MOP 300) Norcodeline Normorphone Oxycodone Oxymorphone Procaine Thebaine Morphine Morphine Morphine Oxycodone Oxycodone Oxycodone Oxymorphone	1,500 300 180 1,800 1,800 5,000 5,000 30,000 5,000 15,000 15,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000
METHYLENE ±) 3,4-Methylenedioxymethamphe 3,4-Methylenedioxyemyl-ampheta ±) 3,4-Methylenedioxyemyl-ampheta ±) 3,4-Methylenedioxyamphetami Codeine -evorphanol Morphine-3-β-D-Glucuronide Ethylmorphine +ydromorphone -devorphanol Morphine-3-β-D-Glucuronide Ethylmorphine -devorphanol Morphine-3-β-D-Glucuronide Ethylmorphine -devorphanol Morphine-3-β-D-Glucuronide Ethylmorphine -ydromorphone Ethylmorphine -ydromorphone -Monoacethylmorphine -dethaqualone Codeine Ethylmorphine -ydromorphone -devorphanol -Monoacethylmorphine -devorphanol	tamine HCI mine ne HCI MORPHINE 200 11.500 80.00 80.00 80.00 80.0000 80.000 80.000 80.000 80.000	(MOP 300) Norcodeline Normorphone Oxycodone Oxymorphone Procaine Thebaine Morphine (MOP 100) Norcodeline Normorphone Oxymorphone Procaine Thebaine Morphine (MOP 100) Norcodeline Normorphone Oxymorphone Oxymorphone Oxycodone Oxymorphone Intelaine Morphine (mol 100) Morphine Norcodeline Norcodeline Normorphone Oxycodone Oxymorphone Tre (OPI 2,000) Morphine Intelaine Thebaine Tre (OPI 1,000) Morphine Norcodeline	1,500
METHYLENE ±) 3,4-Methylenedioxymethamphe 3,4-Methylenedioxyemthylenphe 4) 3,4-Methylenedioxyemthylenphe 5) 3,4-Methylenedioxymphetami Codeine Evorphanol Morphine-3-β-D-Glucuronide Ethylmorphine 1-ydromorphone	tamine HCI mine ne HCI MORPHINE 200 1,500 800 6,600 50,000 800 MORPHINE 80 200 1,000	(MOP 300) Norcodeline Normorphone Oxycodone Oxymorphone Procaine Thebaine Morphine (MOP 100) Norcodeline Normorphone Oxymorphone Oxymorphone Procaine Thebaine	1,500 300 180 1,800 5,000 5,000 30,000 5,000 15,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 2
METHYLENE ±) 3,4-Methylenedioxymethamphe 4),4-Methylenedioxyethyl-amphetat ±) 3,4-Methylenedioxyamphetami 2) 3,4-Methylenedioxyamphetami 2) 3,4-Methylenedioxyamphetami 2) 3,4-Methylenedioxyamphetami 2) 3,4-Methylenedioxyamphetami 20deine 2.evorphanol 3-D-Glucuronide 2.thylmorphine 3-Monoacethylmorphine 3-Morphine-3-β-D-Glucuronide 2.thylmorphine 4-ydrocodone 4-ydromorphone 3-Monoacethylmorphine 2.delene 2.thylmorphine 4.thylmorphine 5.thylmorphine	tamine HCI mine ne HCI MORPHINE 200 1,500 5,000 5,000 5,000 5,000 5,000 1,500 MORPHINE 20,000 1,	(MOP 300) Norcodeline Normorphone Oxymorphone Oxymorphone Procaine Thebaine Morphine Morphine Morphine Morphone Oxymorphone Procaine Thebaine	1,500 300 180 1,800 180 1,800 5,000 5,000 30,000 5,000 15,000 15,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,
### THYLENE ±) 3,4-Methylenedioxymethamphe 4),3-Methylenedioxyethyl-ampheta ±) 3,4-Methylenedioxyamphetami 20deine _evorphanol dorphine-3-β-D-Glucuronide Ethylmorphine +ydromorphone 5-Monoacethylmorphine 20deine _evorphanol dorphine-3-β-D-Glucuronide Ethylmorphine 3-Monoacethylmorphine 3-Monoacethylmorphine 4-dromorphone 5-Monoacethylmorphine 4-dromorphone 5-Monoacethylmorphine 4-dromorphone 5-Monoacethylmorphine 4-dromorphone 5-Monoacethylmorphine 4-dromorphone 5-Monoacethylmorphine 4-dromorphone 5-Monoacethylmorphine 4-dromorphone 1-dromorphone 1-dromo	tamine HCI mine ne HCI MORPHINE 200 1,500 800 6,600 6,600 6,600 6,600 MORPHINE 80 500 1,500 1,00	(MOP 300) Norcodeline Normorphone Oxycodone Oxymorphone Procaine Thebaine Morphine (MOP 100) Norcodeline Normorphone Oxymorphone Procaine Thebaine	1,500 300 180 1,800 5,000 5,000 30,000 5,000 15,000 2,000 1,000 2,000
METHYLENE ±) 3,4-Methylenedioxymethamphe 4),4-Methylenedioxyethyl-ampheta ±) 3,4-Methylenedioxyathyl-ampheta ±) 3,4-Methylenedioxyathyl-ampheta ±) 3,4-Methylenedioxyamphetami Dodeine _everphanol derphine-3-β-D-Glucuronide Ethylmorphine -ydrocodone -ydromorphone	tamine HCI mine ne HCI MORPHINE 200 1,500 5,000 5,000 5,000 5,000 5,000 1,500 MORPHINE 20 1,500 MORPHINE 20 1,500 MORPHINE 20 1,500 MORPHINE 20 1,500 MORPHINE 20,000 1,	(MOP 300) Norcodeline Normorphone Oxymorphone Oxymorphone Procaine Thebaine Morphine Morphine Morphine Morphone Oxymorphone Procaine Thebaine	1,500 300 180 1,500 8,000 80,000 80,000 15,000 15,000 15,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,0
### WETHYLENE ±) 3,4-Methylenedioxymethampheta \$.),4-Methylenedioxyaethyl-ampheta ±) 3,4-Methylenedioxyaethyl-ampheta ±) 3,4-Methylenedioxyamphetami Dodeine _evorphanol dorphine-3-B-D-Glucuronide Ethylmorphine -tydrocodone _evorphanol dorphine-3-B-D-Glucuronide Ethylmorphine -tydrocodone _evorphanol dorphine-3-B-D-Glucuronide Ethylmorphine -tydrocodone _tydrocodone _tydromorphone -tydrocodone _tydromorphone -tydrocodone _tydrocodone _tydromorphone Ethylmorphine -tydrocodone _tydromorphone Ethylmorphine -tydrocodone _tydrocodone _tydromorphone _evorphanol -tydrocodone _tydrocodone _tydromorphone _evorphanol -tydromorphone _evorphanol -ty	Itamine HCI mine ne HCI mine ne HCI MORPHINE 200 1,500 5,000 5,000 5,000 5,000 5,000 1,000 MORPHINE 30 500 300 2,000 1,000 MORPHINE 100 Methaqualon 300 MORPHINE/OPI/ 2,000 1,2,000 1,2,000 1,2,500 1,2,500 1,2,500 1,50	(MOP 300) Norcodeline Normorphone Oxymorphone Oxymorphone Oxymorphone Procaine Thebaine Morphine Morphine Oxycodene Oxymorphone Oxymorphone Oxymorphone Oxycodene Oxymorphone Procaine Thebaine Morphine Morphine Morphine Oxycodene Oxymorphone Procaine Thebaine Morphine Normorphone Oxycodene Oxycodene Oxymorphone Procaine Thebaine Normorphone Oxycodene Oxycodene Oxymorphone Procaine Thebaine Normorphone Oxycodene Oxymorphone Procaine Thebaine Normorphone Oxymorphone Oxymorphone Procaine Thebaine ITHE (PP 1,000) Morphine Normorphone Oxymorphone Oxymorphone Oxymorphone Procaine Thebaine ITHE (PPX) D-Norpropoxyphene PRESSANTS (TCA)	1,500
METHYLENE ±) 3.4-Methylenedioxymethamphe 4).4-Methylenedioxyethyl-ampheta ±) 3.4-Methylenedioxyamphetami 2) 3.4-Methylenedioxyamphetami 2) 3.4-Methylenedioxyamphetami 2) 3.4-Methylenedioxyamphetami 2) 3.4-Methylenedioxyamphetami 2) 3.4-Methylenedioxyamphetami 2) 4-Methylenedioxyamphetami 3) 4-Methylenedioxyamphetami 4) 4-Methylenedioxyamphetami 4) 4-Methylenedioxyamphetami 4) 4-Methylenedioxyamphetami 5) 4-Methylenedioxyamphetami 6) 4-Me	tamine HCI mine ne HCI MORPHINE 200 1,500 800 6,000 800 800 80,000 800 800 800 800 800	(MOP 300) Norcodeline Normorphone Oxycodone Oxymorphone Procaine Thebaline Morphine Morphine Morphine Morphine Normorphone Oxycodone Oxymorphone Oxymorphone Procaine Thebaline Morphine Morphine Oxymorphone Oxymorphone Oxymorphone Oxymorphone Oxymorphone Procaine Thebaline Morphine (MOE 100) Morphine Oxymorphone Oxymorphone Oxymorphone Trebaline Tre (OPI 2,000) Morphine Norcodeline Normorphone Oxymorphone Oxymorphone Oxymorphone Oxymorphone Thebaline Thebaline Thebaline Thebaline Thebaline Thebaline Thebaline Thebaline Oxymorphone Procaine Normorphone Oxymorphone Oxymorphone Procaine Normorphone Oxymorphone Procaine Thebaline Diblike (PCP) Litydroxyphencyclidine LENE (PPX) D-Norpropoxyphene PRESSANTS (TCA) Imingramine Clomipramine Clomipramine Clomipramine	1,500 300 180 1,500 5,000 5,000 5,000 15,000
### METHYLENE ±) 3.4-Methylenedioxyethyl-ampheta #### Methylenedioxyethyl-ampheta ###################################	tamine HCI mine ne HCI MORPHINE 200 1.500 800 6.000 50,000 30,000 400 MORPHINE 80 500 1.00	(MOP 300) Norcodeline Normorphone Oxycodone Oxymorphone Procaine Thebaine Morphine (MOP 100) Norcodeline Normorphone Oxymorphone Procaine Thebaine	1,500 1,500 300 18
### THYLENE ### ### ### ### ### ### ### ### ### #	tamine HCI mine ne HCI MORPHINE 200 1,500 800 6,000 1,500 800 800 800 800 800 800 800 800 800	(MOP 300) Norcodeline Normorphone Oxycodone Oxymorphone Procaine Thebaline Morphine Morphine Morphine Morphine Normorphone Oxymorphone Procaine Thebaline Morphine Oxycodone Oxymorphone Oxymorphone Oxycodone Oxymorphone Oxycodoline Norcodeline Normorphone Oxycodone Oxymorphone Oxycodone Oxymorphone Procaine Thebaline Tre (OPI 1,000) Morphine Norcodeline Norcodeline Normorphone Oxycodone Oxymorphone Procaine Thebaline The (DPI 1,000) Morphine Procaine Thebaline Thebaline Thebaline Thebaline Oxymorphone Procaine Thebaline Thebali	1,500 300 180 1,500 300 180 1,800 5,000 30,000 30,000 15,000 30,000 15,000 10,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 20,000 10,000 20,0
### STHYLENE ### STA 4-Methylenedioxymethamphe ### S.4-Methylenedioxyethyl-ampheta ### S.4-Methylenedioxyethyl-ampheta ### S.4-Methylenedioxyethyl-ampheta ### S.4-Methylenedioxyamphetami Dodeline	tamine HCI mine ne HCI MORPHINE 200 11.500 800 6.000 50,000 800 800 800 800 800 800 800 800 80	(MOP 300) Norcodeline Normorphone Oxycodone Oxymorphone Procaine Thebaine Morphine Morphine Morphine Morphine Morphine Normorphone Oxymorphone Procaine Thebaine Morphine Morphine Morphine Morphine Normorphone Oxymorphone Procaine Thebaine Morphine Oxycodone Oxymorphone Oxycodone Oxymorphone Norcodeline Norcodeline Normorphone Oxycodone Oxymorphone Procaine Thebaine The LoPi 1,000) Morphine Norcodeline Norphine Cycodone Oxymorphone Procaine Thebaine Thebaine Dible (PCP) H-Hydroxyphencyclidine ENE (PPX) D-Norpropoxyphene Procaine Clomipramine Clomipramine Clomipramine Doxepine Maprotiline Promethazine I (TRA) B-Desmethyl-cis-tramadol Phencyclidine	1,500 300 180 1,800 5,000 5,000 30,000 50,000 15,000 15,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 20,000 20,000 10,000 20,000
METHYLENE ±) 3,4-Methylenedioxymethamphe 4),4-Methylenedioxyethyl-ampheta ±) 3,4-Methylenedioxyamphetami 20deine _everphanol dorphine-3-β-D-Glucuronide Ethylmorphine -tydromorphone 3-Monoacethylmorphine -tydrocodone _tydrocodone _tydromorphone 5-Monoacethylmorphine -tydrocodone _tydrocodone _tydromorphone -tydrocodone _tydromorphone -tydrocodone _tydromorphone -tydromorphone _tydrocodone _tydromorphone _tydrocodone _tydromorphone _tydromorphone _tydrocodone _tydromorphone _tydromorphone _tydromorphone _tydrocodone _tydromorphone _tydrocodone _tydromorphone _tydromorphon	tamine HCI mine ne HCI MORPHINE 200 1.500 5.0,000 5.0,000 3.0,000 400 MORPHINE 80 5.000 1.000 MORPHINE 80 5.000 1.000 1.000 MORPHINE 80 5.000 1.000 1.000 1.000 1.000 MORPHINE 80 1.000 1.000 1.000 1.000 MORPHINE 80 1.000	(MOP 300) Norcodeline Normorphone Oxycodone Oxycodone Oxymorphone Procaine Thebaine Morphine Morphine Morphine Morphine Normorphone Oxymorphone Procaine Thebaine Norcodeline Normorphone Oxycodone Oxymorphone Procaine Thebaine Th	1,500
METHYLENE ±) 3,4-Methylenedioxynethyl-amphetati ±) 3,4-Methylenedioxynethyl-amphetati ±) 3,4-Methylenedioxyaethyl-amphetati ±) 3,4-Methylenedioxyaethyl-amphetati ±) 3,4-Methylenedioxyamphetami Dodeine _evorphanol dorphine-3-β-D-Glucuronide Ethylmorphine -tydrocodone -tydromorphone -tydromorphone -tydrocodone -tydromorphone -tydromorphone -tydromorphone -tydromorphone -tydromorphone -tydromorphone -tydromor	MORPHINE	(MOP 300) Norcodeline Normorphone Oxymorphone Oxymorphone Procaine Thebaine Morphine (MOP 100) Norcodeline Normorphone Oxymorphone Oxymorphone Oxymorphone Procaine Thebaine Morphine (MOP 100) Norcodeline Normorphone Oxymorphone Procaine Thebaine Morphine (e (MOL 300) ITE (OPI 2,000) Morphine Norcodeline Norcodeline Norcodeline Normorphone Oxycodone Oxymorphone Procaine Thebaine Thebaine Normorphone Oxycodone Oxymorphone Procaine Thebaine Oxymorphone Procaine Thebaine Normorphone Oxymorphone Procaine Thebaine ITE (OPI 1,000) Morphine Norrodorphone Procaine Thebaine Oxymorphone Oxymorphone Procaine Thebaine Oxymorphone Oxymorphone Oxymorphone Procaine Thebaine Oxymorphone Oxymorphon	1,500
METHYLENE ±) 3.4-Methylenedioxynethyl-amphetati \$.3.4-Methylenedioxynethyl-amphetati \$.3.4-Methylenedioxynethyl-amphetati \$.3.4-Methylenedioxynethyl-amphetati \$.3.4-Methylenedioxynethyl-amphetati \$.3.4-Methylenedioxynethyl-amphetati \$.3.4-Methylenedioxynethyl-amphetati \$.3.4-D-Glucuronide £thylmorphine \$.4-dromorphone \$.4-Monoacethylmorphine \$.4-Monoacethyl	tamine HCI mine ne HCI mine ne HCI mine ne HCI MORPHINE 200 1.500 5.000 5.0000 5.0000 5.0000 MORPHINE 20,000 1.000 MORPHINE 20,000 1.000 MORPHINE 20,000 1.0	(MOP 300) Norcodeline Normorphone Oxymorphone Oxymorphone Procaine Thebaine Morphine MoP 100) Norcodeline Normorphone Oxymorphone Oxymorphone Procaine Thebaine Morphine Morphine Morphine Morphone Oxymorphone Procaine Thebaine Morphine Morphine Morphine (MOL 300) ITE (OPI 2,000) Morphine Normorphone Oxycodone Oxymorphone Procaine Thebaine Normorphone Oxycodone Oxymorphone Procaine Thebaine Normorphone Oxymorphone Procaine Thebaine ITE (OPI 1,000) Morphine Normorphone Oxymorphone Procaine Thebaine ITE (OPI 1,000) Morphine Normorphone Oxymorphone Procaine Thebaine ITE (OPI 1,000) Morphine Normorphone Oxymorphone Procaine Thebaine ITE (OPI 1,000) ITE (OPI 1,000) Morphine Normorphone Oxymorphone Procaine Thebaine ITE (OPI 1,000)	1,500
METHYLENE ±) 3.4-Methylenedioxymethylenedioxymethylenedioxymethylenedioxymethylenedioxymethylenedioxymethylenedioxymethylenedioxymphetami ±) 3.4-Methylenedioxymphetami Dodeine ±) 3.4-Methylenedioxymphetami Dodeine Ethylmorphine	tamine HCI mine ne HCI MORPHINE 200 1,500 8,000 8,000 8,000 8,000 8,000 1,500 MORPHINE 80 20,000 1,000 METAMINE 1,000 12,500 25,000 12,500 MORPHINE/OPI/ 2,000 12,500 13,000 14,500 15,5	(MOP 300) Norcodeline Normorphone Oxymorphone Oxymorphone Procaine Thebaine Morphine MoP 100) Norcodeline Normorphone Oxymorphone Oxymorphone Procaine Thebaine Morphine Morphine Morphine Morphone Oxymorphone Procaine Thebaine Morphine Morphine Morphine (MOL 300) ITE (OPI 2,000) Morphine Normorphone Oxycodone Oxymorphone Procaine Thebaine Normorphone Oxycodone Oxymorphone Procaine Thebaine Normorphone Oxymorphone Procaine Thebaine ITE (OPI 1,000) Morphine Normorphone Oxymorphone Procaine Thebaine ITE (OPI 1,000) Morphine Normorphone Oxymorphone Procaine Thebaine ITE (OPI 1,000) Morphine Normorphone Oxymorphone Procaine Thebaine ITE (OPI 1,000) ITE (OPI 1,000) Morphine Normorphone Oxymorphone Procaine Thebaine ITE (OPI 1,000)	1,500 300 18
METHYLENE ±) 3.4-Methylenedioxymethamphe 5).4-Methylenedioxyethyl-ampheta ±) 3.4-Methylenedioxyethyl-ampheta ±) 3.4-Methylenedioxyethyl-ampheta ±) 3.4-Methylenedioxyethyl-ampheta ±) 3.4-Methylenedioxymphetami Dodeine Ethylmorphine -tydrocodone -tydromorphine -tydrocodone -tydromorphine -tydrocodone -tydromorphine -tydrocodone -tydromorphine -tydromorphine -tydrocodone -tydromorphine -tydrocodone -tydromorphine -tydrocodone -tydromorphine -tydrocodone -tydromorphine -tydrocodone -tydrocodone -tydrocodone -tydromorphine -tydrocodone -tydrocodone -tydromorphine -tydrocodone -tydromorphine -tydrocodone -tydromorphine -tydrocodone -tydromorphine -tydrocodone -tydrocodone -tydromorphine -tydrocodone -tydromorphine -tydromorphine -tydrocodone -tyd	tamine HCI mine ne HCI mine ne HCI mine ne HCI MORPHINE 200 1.500 5.000 5.000 5.000 MORPHINE 300 5.000 3.000 1.000 MORPHINE 300 3.000 1.000 MORPHINE 300 MORPHINE 300 MORPHINE 300 MORPHINE 300 MORPHINE 300 MORPHINE 400 MORPHINE 400 MORPHINE 500 MORPHINE 500 MORPHINE 500 1.000 MORPHINE 500 1.500 1.500 MORPHINE 500 KETAMINE 500 COCycodor 500 COCYCODO	(MOP 300) Norcodeline Normorphone Oxymorphone Oxymorphone Oxymorphone Procaine Thebaine Morphine Morphine Morphine Morphine Morphine Morphine Normorphone Oxymorphone Procaine Thebaine Morphine Morphine Morphine Morphine Morphine Morphine Morphine Normorphone Oxymorphone Procaine Thebaine Normorphone Normorphone Oxycodone Oxymorphone Procaine Thebaine Normorphone Oxycodone Oxymorphone Procaine Thebaine Morphine Normorphone Oxymorphone Procaine Thebaine ITE (OPI 1,000) INE (ICE) Inipramine Oxepine Maprotiline Promethazine Perphenazine I (TRA) Inipramine Oxepine Maprotiline Promethazine Perphenazine I (TRA) III-O-Desmethyl venlafaxine KET1,000) I(KET300) I(KET300) I(KET300)	1,500 300 180 180 1,500 8,000 8,000 80,000 30,000 15,000 15,000 15,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000
METHYLENE ±) 3.4-Methylenedioxymethyampheta 5,4-Methylenedioxyethyl-ampheta ±) 3.4-Methylenedioxyethyl-ampheta ±) 3.4-Methylenedioxyethyl-ampheta ±) 3.4-Methylenedioxyethyl-ampheta ±) 3.4-Methylenedioxyamphetami Dodeine _evorphanol Morphine-3-B-D-Glucuronide Ethylmorphine -ydromorphone -ydromorphone 5-Monoacethylmorphine Dodeine _evorphanol Morphine-3-B-D-Glucuronide Ethylmorphine -ydromorphone 5-Monoacethylmorphine Methaqualone Dodeine Ethylmorphine -ydromorphone -evorphanol -Monoacetylmorphine Morphine 3-B-D-glucuronide Ethylmorphine -ydromorphone -evorphanol -Monoacetylmorphine Morphine 3-B-D-glucuronide Dodeine Ethylmorphine -ydromorphone -evorphanol 5-Monoacetylmorphine Morphine 3-B-D-glucuronide Dodeine Ethylmorphine -ydromorphone -evorphanol 5-Monoacetylmorphine Morphine 3-B-D-glucuronide Dehencyclidine D-Propoxyphene T Nortriplyline Promazine Desipramine Promazine Desipramine Vyclobenzaprine -Desmethyl-cis-tramadol Procyclidine Ketamine Ketamine Coxycodone Doxycodone	tamine HCI mine ne HCI mine ne HCI mine ne HCI MORPHINE 200 1,500 5,000 5,000 3,000 400 MORPHINE 300 2,000 MORPHINE 400 MORPHINE 400 MORPHINE 400 MORPHINE 500 50,000 1,000 MORPHINE 500 1,000 MORPHINE 600 1,000 MORPHINE 600 MOR	(MOP 300) Norcodeline Normorphone Oxymorphone Oxymorphone Procaine Thebaline Morphine Morphine Morphine Morphine Morphine Morphine Normorphone Oxymorphone Procaine Thebaline Morphine Morphine Morphine Morphine Morphine Morphine Morphine Normorphone Oxymorphone Procaine Thebaline Normorphone Oxycodone Oxymorphone Procaine Normorphone Normorphone Oxycodone Oxymorphone Procaine Thebaline Normorphone Oxymorphone Procaine Thebaline Normorphone Oxymorphone Procaine Thebaline Normorphone Oxymorphone Procaine Thebaline ITE (PP 1,000) Morphine Normorphone Oxymorphone Procaine Thebaline ITE (OPI 1,000) Morphine Normorphone Oxymorphone Procaine Thebaline ITE (OPI 1,000) Morphine Normorphone Oxymorphone Procaine Thebaline ITE (OPI 1,000) Normorphone Normorphone Normorphone Normorphone Naloxone	1,500 300 180 1,500 180 1,500 5,000 5,000 30,000 50,000 15,000 15,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20
### STHYLENE ### As A-Methylenedioxyethyl-ampheta ### As A-Methylenedioxyethylenedioxyethyl-ampheta ### As A-Methylenedioxyethylenedioxyethylenedioxyethylenedioxyethyl-ampheta ### As A-Methylenedioxyethylenediox	tamine HCI mine ne HCI mine ne HCI mine ne HCI MORPHINE 200 1.500 5.000 5.000 5.000 3.000 400 MORPHINE 300 5.000 3.000 1.000 MORPHINE 300 MORPHINE 300 300 1.000 MORPHINE 300 MORPHINE 300 MORPHINE 300 MORPHINE 300 MORPHINE 300 1.500 MORPHINE 300 1.500 1.500 1.500 1.500 1.500 1.500 MORPHINE 300 1.500 1.500 1.500 MORPHINE 300 1.500 1.500 MORPHINE 300 1.500 1.500 MORPHINE 300 COST MORPHINE 300 MORPHINE 300 MORPHINE 300 COST MORPHINE 300 MORPHINE 3	(MOP 300) Norcodeline Normorphone Oxymorphone Oxymorphone Oxymorphone Oxymorphone Oxymorphone Oxymorphone Oxymorphone Oxymorphone Oxycodeline Normorphone Oxycodeline Normorphone Oxycodeline Normorphone Oxycodeline Intebaline Morphine Morphine Morphine Oxycodeline Normorphone Oxymorphone Procaline Intebaline Normorphone Oxycodeline Normorphone Oxycodeline Normorphone Oxycodeline Normorphone Oxymorphone Procaline Intebaline Inte (DP 1,000) Morphine Norcodeline Normorphone Oxymorphone Procaline Intebaline Inte (PCP) H-Hydroxyphencyclidine IENE (PCP) H-Hydroxyphencyclidine IENE (PX) Do-Norpropoxyphene PRESSANTS (TCA) Imipramine Oxepine Maprotiline Promethazine I(TRA) I-O-Desmethyl-cis-tramadol Phencyclidine I(TRA) I-O-Desmethyl-cis-tramadol Phencyclidine KET1,000) (KET300) I. (KET300) I. (KET300) I. (KET300) I. (KET300) I. (J-Nicotine OXT 2000 I-Nicotine OXT 2000 I-Nicotine	1.500 300 180 1.800 180 1.800 50,000 30,000 50,000 15,000 16,250 16,000 16,250 16,000 17,000 18,500
### THYLENE ### ### ### ### ### ### ### ### ### #	tamine HCI mine ne HCI MORPHINE 200 1.500 5.0,000 5.0,000 3.000 1.000 Methaqualon 300 MoRPHINE/OPI 20,000 1.000 MoRPHINE/OPI 20,000 1.000 Methaqualon 300 MoRPHINE/OPI 20,000 1.000 MORPHINE/OPI 20,000 MORPHINE	(MOP 300) Norcodeline Normorphone Oxycodone Oxycodone Oxymorphone Procaine Thebaine Morphine Morphine Morphine Morphine Normorphone Oxymorphone Procaine Thebaine Norcodeline Normorphone Oxycodone Oxymorphone Procaine Thebaine Th	1,500 300 180 1,500 180 1,500 5,000 5,000 30,000 50,000 15,000 15,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 10,000 20,000 20,000 10,000 20
METHYLENE ±) 3.4-Methylenedioxymethylenedio	tamine HCI mine ne HCI mine ne HCI MORPHINE 200 1,500 5,000 5,000 5,000 1,000 MORPHINE 300 2,000 1,000 MORPHINE 300 MORPHINE 300 MORPHINE 300 MORPHINE 300 1,000 MORPHINE 300 1,000 1,000 MORPHINE 300 1,000 1,000 MORPHINE 300 1,000 1,000 1,000 1,000 MORPHINE 300 1,000 1,000 1,000 MORPHINE 300 1,000 1,000 MORPHINE 300 1,000 1,000 MORPHINE 300 1,000 1,000 MORPHINE 300 1,000 MORPHINE 4,000 1,000 MORPHINE 5,000 MORP	(MOP 300) Norcodeline Normorphone Oxycodone Oxymorphone Procaine Thebaline Morphine (MOP 100) Norcodeline Normorphone Oxymorphone Oxymorphone Oxymorphone Procaine Thebaline Morphine (MOP 100) Norcodeline Normorphone Oxymorphone Procaine Thebaline Morphine (MOP 300) ITE (OPI 2,000) Morphine Norcodeline Normorphone Oxycodone Oxymorphone Procaine Thebaline IThebaline Oxymorphone Procaine Thebaline IThebaline IThebaline IThebaline Oxymorphone Procaine Thebaline Normorphone Oxymorphone Procaine Thebaline IThebaline I	1,500 300 18

Fenfluramine Norfontanyl	40,000	Fentanyl	100
Norfentanyl	20	Sufentanyl	60,000
Pipamperon	25,000 Fen	Risperdal stanyl (FYL10)	10,000
Alfentanyl	300,000	Perphenazine	2,500
Fenfluramine	20,000	Fentanyl	2,500
Vorfentanvl	10	Sufentanyl	30,000
Pipamperon	12,500	Risperdal	5,000
,		: Marijuana (K2-50)	1-1-1-1
JWH-018 5-Pentanoic acid			50
JWH-073 4-butanoic acid			50
JWH-018 4-Hydroxypentyl			400
JWH-018 5-Hydroxypentyl			600
JWH-073 4-Hydroxybutyl r	netabolite		300
JWH-018 N-Propanoic aci	d		30
JWH-019 6-Hydroxyhexyl			1,000
JWH-122 N-4-Hydroxypen	tyl		1,000
RCS4 N-5-Carboxypentyl			45,000
MAM2201 N-Pentanoic ac			65
JWH-210 N-5-Carboxypen JWH-398 N-Pentanoic acid			400 350
JWH-200 6-Hydroxyindole			600
JWH-073 N-2-Hydroxybuty			1,000
JWH-019 5-Hydroxyhexyl			1,000
JWH-018			7,000
AM2201 N-(4-hydroxypent	yl)		700
JWH-073 N-(3-hydroxybut			450
to ity dioxybut		Marijuana (K2-30)	1.50
JWH-018 5-Pentanoic acid			30
JWH-073 4-butanoic acid			30
JWH-018 4-Hydroxypentyl			250
JWH-018 5-Hydroxypentyl			360
JWH-073 4-Hydroxybutyl r	netabolite		180
JWH-018 N-Propanoic aci	d		18
JWH-019 6-Hydroxyhexyl			600
JWH-122 N-4-Hydroxypen	tyl		600
RCS4 N-5-Carboxypentyl			27000
MAM2201 N-Pentanoic ac			39
JWH-210 N-5-Carboxypen			240
JWH-398 N-Pentanoic acid			210
JWH-200 6-Hydroxyindole JWH-073 N-2-Hydroxybut			360
JWH-073 N-2-Hydroxybuty JWH-019 5-Hydroxyhexyl	ĮI .		600 600
JVVI ("O 19 5-Hydroxynexyl			DUU
IWH-018			4200
	vI)		4200 420
AM2201 N-(4-hydroxypent			420
AM2201 N-(4-hydroxypent JWH-073 N-(3-hydroxybut Ethyl glucuronide	yl) Ethyl glud K2+	curonide (ETG 500)	420 270 500
AM2201 N-(4-hydroxypent JWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA pentanoic aci AB-PINACA N-(4-hydroxyj ADB-PINACA N-(4-hydroxyj ADB-PINACA N-(4-hydroxyj	K2+ d metabolite pentyl) metabolite ypentyl) metabolite		420 270 500 10 10
AM2201 N-(4-hydroxypent JWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA pentanoic aci AB-PINACA N-(4-hydroxy ADB-PINACA N-(5-hydrox ADB-PINACA N-(5-hydrox	yi) Ethyl glue K2+ d metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite		420 270 500 10 10 15 20
AM2201 N-(4-hydroxypent) AM2-073 N-(3-hydroxybut) Ethyl glucuronide AB-PINACA pentanoic aci AB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy) ADB-PINACA N-(5-hydrox) 5-fluoro AB-PINACA N-(5-hydrox) 5-fluoro AB-PINACA N-(4-	K2+ d metabolite pentyl) metabolite ypentyl) metabolite ypentyl) metabolite hydroxypentyl)		420 270 500 10 10 15 20 20
AM2201 N-(4-hydroxypent WH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA pentanoic aci AB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydrox Elluoro AB-PINACA N-(4-hydrox ADB-PINACA N-(4-hydrox	K2+ d metabolite pentyl) metabolite ypentyl) metabolite hydroxypentyl) cid metabolite		420 270 500 10 15 20 20
AM2201 N-(4-hydroxypent WH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA Pentanolc aci AB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(5-hydroxy ADB-PINACA N-(5-hydroxy ABB-PINACA N-(5-hydroxy	K2+ d metabolite pentyl) metabolite ypentyl) metabolite hydroxypentyl) cid metabolite		420 270 500 10 10 15 20 20 20 20
AM2201 N-(4-hydroxypent IWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy) ADB-PINACA N-(5-hydrox) Filuror AB-PINACA N-(4-ADB-PINACA Pentanoic a AB-PINACA N-(5-hydroxy) Filuror AB-PINACA N-(5-hydroxy) Filuror AB-PINACA N-(5-hydroxy) Filuror AB-PINACA N-(5-hydroxy)	K2+ d metabolite pentyl) metabolite ypentyl) metabolite hydroxypentyl) cid metabolite		\$20 \$70 \$00 \$10 \$15 \$20 \$20 \$20 \$30 \$50
AM2201 N-(4-hydroxypent IWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA Pertanoic aci AB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy 5-fluoro AB-PINACA N-(4-hydroxy) 5-fluoro AB-PINACA AB-PINACA N-(5-hydroxy) 5-fluoro AB-PINACA AB-PINACA AB-PINACA	K2+ d metabolite pentyl) metabolite ypentyl) metabolite hydroxypentyl) cid metabolite		420 270 500 10 10 15 20 20 20 30 50
AM2201 N-(4-hydroxypent WH-073 N-(3-hydroxybut BEHyl glucuronide AB-PINACA Pentanoic aci AB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(5-hydrox S-fluoro AB-PINACA N- AB-PINACA Pentanoic a AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA	K2+ d metabolite pentyl) metabolite ypentyl) metabolite hydroxypentyl) cid metabolite		420 270 500 10 10 15 20 20 20 20 30 50 100
AM2201 N-(4-hydroxypent WH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA Pentanoic aci AB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy 5-fluoro AB-PINACA N-(4- ADB-PINACA N-(5-hydroxy) 5-fluoro AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA	K2+ d metabolite pentyl) metabolite ypentyl) metabolite hydroxypentyl) cid metabolite		420 270 500 10 10 15 20 20 20 30 50 100 150 250
AM2201 N. (4-hydroxypent WH-073 N-(3-hydroxybut BEHyl glucuronide AB-PINACA P(4-hydrox) AB-PINACA N-(4-hydrox) ADB-PINACA N-(4-hydrox) ADB-PINACA N-(4-hydrox) B-B-PINACA N-(4-hydrox) B-B-PINACA N-(5-hydroxy) B-B-B-B-B-B-B-B-B-B-B-B-B-B-B-B-B-B-B-	K2+ d metabolite pentyl) metabolite ypentyl) metabolite hydroxypentyl) cid metabolite		420 270 500 10 10 15 20 20 20 30 50 100 150 250
AM2201 N. (4-hydroxypent IWH-073 N. (3-hydroxybut Ethyl glucuronide AB-PINACA P. (4-hydroxy ADB-PINACA N. (4-hydroxy ADB-PINACA N. (4-hydroxy ADB-PINACA N. (5-hydrox) Filuror AB-PINACA N. (4-hydrox BB-PINACA N. (5-hydroxy Filuror AB-PINACA AB-PINACA N. (5-hydroxy Filuror AB-PINACA AB-PINACA N. (5-hydroxy Filuror AB-PINACA AB-PINACA N. (4-hydroxy Filuror AB-PINACA AB-PINACA AB-PINACA AB-PINACA (AB-PINACA PINACA (AB-PINACA	K2+ d metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite hydroxypentyl) cid metabolite bentyl) metabolite pentyl) metabolite		420 270 500 10 10 15 20 20 20 30 50 100 155 20 20 20 30 50 100 100 100 100 100 100 100
AM2201 N-(4-hydroxypent WH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA Picta-(4-hydroxy) AB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy) 5-fluoro AB-PINACA N-(4-hydroxy) 5-fluoro AB-PINACA AB-PINACA AB-PINACA N-(5-hydroxy) 5-fluoro AB-PINACA AB-FINACA N-(5-hydroxy) 5-fluoro AB-PINACA AB-FINACA AB-PINACA 3-fluoro AB-PINACA 3-fluoro AB-PINACA 3-fluoro (AB-PINACA 3-fluoro (AB-PINACA)	K2+ d metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite hydroxypentyl) cid metabolite bentyl) metabolite pentyl) metabolite		#20 270 #500 #10 #15 #20 #20 #20 #20 #30 #50 #100 #150 #250 #1000 >10,000
AM2201 N-(4-hydroxypent WH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA pentanoic aci AB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydrox ADB-PINACA N-(5-hydrox) Filuoro AB-PINACA N-(4-hydrox AB-PINACA N-(5-hydrox) 5-fluoro AB-PINACA AB-PINACA N-(5-hydrox) 5-fluoro AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA 5-fluoro AB-PINACA AB-PINACA (AB-48) APINACA (AKB-48) APINACA (AKB-48) APINACA (AKB-48) 5-hyd CUMYL-THPINACA	K2+ d metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite hydroxypentyl) cid metabolite bentyl) metabolite pentyl) metabolite		420 270 500
AM2201 N-(4-hydroxypent IWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA N-(4-hydroxybut BB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy ADB-PINACA N-(5-hydrox) Filuror AB-PINACA N-(4-hydrox BB-PINACA N-(5-hydroxy) Filuror AB-PINACA AB-PINACA N-(5-hydroxy) Filuror AB-PINACA AB-PINACA AB-PINACA AB-PINACA N-(5-hydroxy) AB-PINACA (AB-FINACA AB-PINACA (AB-FI	Ethyl glue K2+ d metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite bydroxypentyl) did metabolite bentyl) metabolite bentyl) metabolite bentyl) metabolite		#20 270 \$00 10 10 15 20 20 20 30 50 100 150 20 20 30 50 100 150 20 20 20 20 30 50 100 100 100 100 100 100 100
AM2201 N-(4-hydroxypent WH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA Pertanoic aci AB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy) 5-fluoro AB-PINACA N-(5-hydroxy) 5-fluoro AB-PINACA N-(5-hydroxy) 5-fluoro AB-PINACA AB-PINACA N-(5-hydroxy) 5-fluoro AB-PINACA AB-FUBINACA AB-FUBINACA AB-FUBINACA AB-FUBINACA BA-FUBINACA BA-FUBINACA Coltro AB-PINACA Coltro AB-PINACA	Ethyl glue K2+ d metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite bydroxypentyl) did metabolite bentyl) metabolite bentyl) metabolite bentyl) metabolite		420 270 500
AM2201 N I-(4-hydroxypent IWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA pentanoic aci AB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(5-hydroxy 5-fluoro AB-PINACA N-(5-hydroxy 5-fluoro AB-PINACA N-(5-hydroxy 5-fluoro AB-PINACA AB-PINACA N-(5-hydroxy 5-fluoro AB-PINACA AB-PINACA AB-PINACA AB-PINACA (AR-48) S-fluoro AB-PINACA S-fluoro AB-PINACA S-fluoro AB-PINACA S-fluoro AB-PINACA S-fluoro AB-PINACA S-fluoro AB-PINACA S-fluoro AB-PINACA S-fluoro AB-PINACA AB-PINACA (AR-48) S-fluoro AB-PINACA AB-PINACA (AR-48) S-fluoro AB-PINACA AB-PINACA (AR-48) S-fluoro AB-PINACA AB-PINACA (AR-48) S-fluoro AB-PINACA AB-CHMINACA metabolite PX 1 (5-fluoro APP-PICA)	Ethyl glue K2+ d metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite hydroxypentyl) bid metabolite bydroxypentyl) bid metabolite roxypentyl metabolite		420 270
AM2201 N-(4-hydroxypent IWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA N-(4-hydroxybut AB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy) 5-fluoro AB-PINACA N-(4- ADB-PINACA N-(5-hydroxy) 5-fluoro AB-PINACA AB-PINACA N-(5-hydroxy) 5-fluoro AB-PINACA AB-PINACA N-(5-hydroxy) 5-fluoro AB-PINACA AB-PINACA (AKB-48) APINACA	Ethyl glue K2+ d metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite bydroxypentyl) did metabolite bentyl) metabolite bentyl) metabolite bentyl) metabolite bentyl) metabolite bentyl) metabolite		#20 270 #500 #10 #15 20 20 20 20 30 50 100 150 250 1000 >10,000 >10,000 >100,000 >100,000
AMZ201 N(4-hydroxypent WH-073 N(3-hydroxybut Ethyl glucuronide AB-PINACA Pentanoic aci AB-PINACA N(4-hydroxy) ADB-PINACA N(4-hydroxy) ADB-PINACA N(4-hydroxy) ADB-PINACA N(5-hydroxy) ADB-PINACA N(5-hydroxy) ADB-PINACA N(5-hydroxy) S-fluoro AB-PINACA AB-PINACA N(5-hydroxy) S-fluoro AB-PINACA AB-PIN	Ethyl glue K2+ d metabolite bentyl) metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite hydroxypentyl) cid metabolite bentyl) metabolite bentyl) metabolite roxypentyl metabolite roxypentyl metabolite		420 270
AM2201 N-(4-hydroxypent IWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA Pentanoic aci BB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(5-hydroxy Filuror AB-PINACA N-(5-hydroxy Filuror AB-PINACA N-(5-hydroxy Filuror AB-PINACA AB-PINACA N-(5-hydroxy Filuror AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA (AB-PINACA AB-PINACA (AB-PINACA AB-PINACA (AB-PINACA AB-PINACA (AB-B) AB-P	Ethyl glue K2+ d metabolite bentyl) metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite hydroxypentyl) cid metabolite bentyl) metabolite bentyl) metabolite roxypentyl metabolite roxypentyl metabolite		420 270
AM2201 N-(4-hydroxypent WH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA Pentanoic aci AB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydrox) ADB-PINACA N-(4-hydrox) ADB-PINACA N-(5-hydrox) ABB-PINACA N-(5-hydrox) ABB-PINACA N-(5-hydrox) ABB-PINACA Pentanoic a ABPINACA PINACA N-(4-ADB-PINACA N-(4-ADB-PINACA N-(4-ADB-PINACA N-(5-hydroxy) ABB-PINACA ABB-PINACA ABB-PINACA (ABB-4B) ABB-PINACA (AKB-48) ABF-UBINACA (AKB-48) APINACA (AKB-48	Ethyl glue K2+ d metabolite bentyl) metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite hydroxypentyl) cid metabolite bentyl) metabolite bentyl) metabolite roxypentyl metabolite roxypentyl metabolite		420 270
AM2201 N-(4-hydroxypent IWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA pentanoic aci AB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(5-hydroxy ADB-PINACA N-(5-hydroxy B-fluora AB-PINACA N-(4-hydroxy B-fluora AB-PINACA N-(5-hydroxy B-fluora AB-PINACA N-(5-hydroxy B-fluora AB-PINACA AB-PINACA N-(5-hydroxy B-fluora AB-PINACA AB-PINACA N-(5-hydroxy B-fluora AB-PINACA AB-PINACA AB-PINACA AB-PINACA B-Fluora AB-PINACA S-fluora AB-PINACA S-fluora AB-PINACA APINACA (AKB-48) 5-hydroxy B-Fluora AB-PINACA AB-PINACA (AKB-48) 5-hydroxy B-Fluora AB-PINACA S-fluora AB-	Ethyl glue K2+ d metabolite bentyl) metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite hydroxypentyl) cid metabolite bentyl) metabolite bentyl) metabolite roxypentyl metabolite roxypentyl metabolite		420 270
AM2201 N(4-hydroxypent IWH-073 N(3-hydroxybut Ethyl glucuronide AB-PINACA Pentanoic aci AB-PINACA N(4-hydroxy ADB-PINACA N(4-hydroxy ADB-PINACA N(4-hydroxy ADB-PINACA N(4-hydroxy ADB-PINACA N(5-hydroxy Filuror AB-PINACA N(4-hydrox AB-PINACA N(5-hydroxy Filuror AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA (AB-PINACA AB-PINACA (AB-PINACA	Ethyl glue K2+ d metabolite bentyl) metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite hydroxypentyl) cid metabolite bentyl) metabolite bentyl) metabolite roxypentyl metabolite roxypentyl metabolite		420 270
AM2201 N-(4-hydroxypent WH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA Pentanoic aci AB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy) ADB-PINACA N-(5-hydroxy) BA-PINACA N-(5-hydroxy) 5-fluoro AB-PINACA AB-PINACA N-(5-hydroxy) 5-fluoro AB-PINACA AB-PINACA AB-PINACA AB-PINACA (AB-PINACA AB-PINACA (AB-PINACA AB-PINACA (AB-PINACA S-fluoro AB-PINACA APINACA (AKB-48) 5-fluoro AB-PINACA ARINACA (AKB-48) 5-fluoro AB-PINACA	Ethyl glue K2+ d metabolite pentyl) metabolite pentyl) metabolite pypentyl) metabolite pypentyl) metabolite pypentyl) metabolite pypentyl) metabolite pydentyl) metabolite pentyl) metabolite pentyl) metabolite roxypentyl metabolite 8 M2 GA MB-PINACA) GA		420 270
JWH-073 N-(3-hydroxybut Eithyl glucuronide AB-PINACA pentanoic aci AB-PINACA N-(4-hydroxy AB-PINACA N-(4-hydroxy AB-PINACA N-(4-hydroxy AB-PINACA N-(5-hydrox AB-PINACA N-(5-hydroxy 5-fluoro AB-PINACA AB-PINACA N-(5-hydroxy 5-fluoro AB-PINACA BIUDO AB-PINACA BIUDO AB-PINACA AB-PINACA BIUDO AB-PINACA AB-PINACA CIMYL-TIPINACA BIUDO AB-PINACA AB-PINACA CIMYL-PIPINACA BIUDO AB-PINACA CIMYL-PIPINACA BIUDO	Ethyl glux K2+ d metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite phydroxypentyl id metabolite bentyl) metabolite bentyl metabolite		420
AM2201 N I-(4-hydroxypent IWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA Pentanoic aci RB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(5-hydroxy ADB-PINACA N-(5-hydroxy ADB-PINACA N-(5-hydroxy Indra ADB-PINACA N-(5-hydroxy Indra ADB-PINACA N-(5-hydroxy Indra ADB-PINACA AB-PINACA N-(5-hydroxy Indra ADB-PINACA AB-PINACA (ARB-48) B-RUBINACA AB-PINACA AB-PINACA AB-PINACA B-RUBINACA B-RUBIN	Ethyl glux K2+ d metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite phydroxypentyl id metabolite bentyl) metabolite bentyl metabolite		420 270
AM2201 N(4-hydroxypent WH-073 N(3-hydroxybut Ethyl glucuronide AB-PINACA Pentanoic aci AB-PINACA N(4-hydroxy ADB-PINACA N(4-hydrox ADB-PINACA N(4-hydrox ADB-PINACA N(4-hydrox ADB-PINACA N(5-hydrox) Filuror AB-PINACA N(4-hydrox AB-PINACA N(5-hydrox) Filuror AB-PINACA N(4-hydrox AB-PINACA N(5-hydrox) Filuror AB-PINACA AB-FINACA N(5-hydrox) Filuror AB-PINACA AB-PINACA (AKB-48) AB-PINACA (AKB-48) APINACA (AK	Ethyl glue K2+ d metabolite bentyl) metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite hydroxypentyl) cid metabolite bentyl) metabolite bentyl) metabolite roxypentyl metabolite M2 A) MB-PINACA) A Md-PINACA) A Md-PINACA) A Md-PINACA) A Md-PINACA) A Md-PINACA) A Md-PINACA		420
AM2201 N-(4-hydroxypent IWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA Pentanoic aci RB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(5-hydroxy ADB-PINACA N-(5-hydroxy Filuror AB-PINACA N-(5-hydroxy Filuror AB-PINACA N-(5-hydroxy Filuror AB-PINACA AB-PINACA N-(5-hydroxy Filuror AB-PINACA AB-PINACA N-(5-hydroxy AB-PINACA AB	Ethyl glux K2+ d metabolite pentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite pontyl) metabolite pontyl) metabolite pontyl) metabolite pontyl) metabolite pontyl) metabolite pontyl) metabolite M2 A) MB-PINACA) A dole metabolite tabolite tyl) metabolite Zolg ylic acid	(AB-PINACA)	420
AM2201 N-(4-hydroxypent IWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA Pentanoic aci AB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(5-hydroxy ADB-PINACA N-(5-hydroxy ADB-PINACA N-(5-hydroxy ADB-PINACA N-(5-hydroxy B-FIUNACA N-(5-hydroxy B-FIUNACA N-(5-hydroxy AB-PINACA AB-PINACA N-(5-hydroxy AB-PINACA N-(5-hydroxy AB-PINACA N-(5-hydroxy AB-PINACA AB-PINACA N-(5-hydroxy AB-PINACA AB-PINACA N-(5-hydroxy AB-PINACA AB-PIN	Ethyl glut K2+ d metabolite bentyl) metabolite pentyl) metabolite pypentyl) metabolite pypentyl) metabolite pypentyl) metabolite pypentyl) metabolite pypentyl) metabolite pontyl) metabolite pontyl) metabolite pentyl) metabolite pentyl) metabolite pentyl) metabolite pentyl) metabolite pentyl) metabolite pontyl pentyl penty	oldem (ZOL50)	420 270
AM2201 N-(4-hydroxypent IWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA Pentanoic aci AB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydrox) - Fluoro AB-PINACA N-(4-hydrox) - Fluoro AB-PINACA N-(4-hydrox) - Fluoro AB-PINACA N-(4-hydrox) - Fluoro AB-PINACA - AB-PINACA N-(4-hydrox) - Fluoro AB-PINACA - AB-PINACA N-(4-hydrox) - Fluoro AB-PINACA - AB-PINACA (AKB-48) - Fluoro AB-PINACA - S-Fluoro AB-PINACA	Ethyl glux K2+ d metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite phydroxypentyl metabolite bentyl) metabolite bentyl) metabolite bentyl) metabolite bentyl) metabolite Toxypentyl metabolite bentyl) metabolite bentyl) metabolite Zolg ylic acid Methor [1,000]	(AB-PINACA) poidem (ZOL50) athinone (MCAT) Mephedrone	420 270
AM2201 N-(4-hydroxypent IWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA Pentanoic aci AB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydrox) - Fluoro AB-PINACA N-(4-hydrox) - Fluoro AB-PINACA N-(4-hydrox) - Fluoro AB-PINACA N-(4-hydrox) - Fluoro AB-PINACA - AB-PINACA N-(4-hydrox) - Fluoro AB-PINACA - AB-PINACA N-(4-hydrox) - Fluoro AB-PINACA - AB-PINACA (AKB-48) - Fluoro AB-PINACA - S-Fluoro AB-PINACA	Ethyl glue K2+ d metabolite bentyl) metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite som postorite bydroxypentyl) cid metabolite bentyl) metabolite bentyl) metabolite roxypentyl metabolite bydroxypentyl M2 A3 MB-PINACA) A4 MB-PINACA) A5 MG-PINACA A6 MG-PINACA A7 MG-PINACA MG-PINACA A7 MG-PINACA MG-PINAC	oldem (ZOL50) athinone (MCAT) Mephedrone Cathinone	420 270
AM2201 N-(4-hydroxypent IWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA Pentanoic aci RB-PINACA N-(4-hydroxybut BB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(5-hydroxy Filuror AB-PINACA N-(5-hydroxy Filuror AB-PINACA N-(5-hydroxy Filuror AB-PINACA AB-PINACA N-(5-hydroxy Filuror AB-PINACA AB-PINACA AB-PINACA AB-PINACA (AB-PINACA AB-PINACA (AB-PINACA AB-PINACA (AB-PINACA AB-PINACA (AB-B) AB-PINACA AB-PINAC	Ethyl glu K2+ d metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite bentyl) metabolite bentyl) metabolite bentyl) metabolite bentyl) metabolite bentyl) metabolite Toxypentyl metabolite bentyl) metabolite Toxypentyl metabolite bentyl) metabolite tabolite tyl) metabolite tabolite tyl) metabolite Zolg ylic acid Methot 1,000 >100,000 Meplexicon Meplexicon Meplexicon Meplexicon Metabolite Methot Meplexicon Meplexicon Meplexicon Meplexicon K2+ Metabolite Methot Meplexicon Meplexicon Meplexicon Mexicon M	idem (ZOL50) athinone (MCAT) Mephedrone (Cathinone hedrone (MEP)	420 270
AM2201 N-(4-hydroxypent IWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA pentanoic aci AB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy) ADB-PINACA N-(5-hydroxy) 5-fluoro AB-PINACA N-(4-ADB-PINACA N-(4-ADB-PINACA N-(4-ADB-PINACA N-(4-ADB-PINACA N-(4-ADB-PINACA N-(4-ADB-PINACA N-(4-ADB-PINACA N-(4-B)-PINACA N-(4-ADB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA (AKB-48) 5-fluoro AB-PINACA APINACA (AKB-48) 5-fluoro ADB-PINACA APINACA (AKB-48) 5-fluoro ADB-PINACA APINACA (AKB-48) 5-fluoro ADB-PINACA APINACA (AKB-48) 5-fluoro ABB-RO-HINACA MBC-HURINACA M-PINACA CUMYL-PICA S-fluoro APP-PICA) 1-fluoro APP-PICA S-fluoro APP-PICA S-f	Ethyl glux K2+ d metabolite pentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite pentyl) metabolite MB-PINACA) A A MB-PINACA) A JA MB-PINACA) A Metabolite Tologia acid Methct 1,1,000 J-100,000 Mepl S00	oldem (ZOL50) antinone (MECAT) Mephadrone Cathinone Methathinone	420 270
AM2201 N-(4-hydroxypent IWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA pentanoic aci AB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy) ADB-PINACA N-(4-hydroxy) ADB-PINACA N-(5-hydroxy) 5-fluoro AB-PINACA N-(4-ADB-PINACA N-(4-ADB-PINACA N-(4-ADB-PINACA N-(4-ADB-PINACA N-(4-ADB-PINACA N-(4-ADB-PINACA N-(4-ADB-PINACA N-(4-B)-PINACA N-(4-ADB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA (AKB-48) 5-fluoro AB-PINACA APINACA (AKB-48) 5-fluoro ADB-PINACA APINACA (AKB-48) 5-fluoro ADB-PINACA APINACA (AKB-48) 5-fluoro ADB-PINACA APINACA (AKB-48) 5-fluoro ABB-RO-HINACA MBC-HURINACA M-PINACA CUMYL-PICA S-fluoro APP-PICA) 1-fluoro APP-PICA S-fluoro APP-PICA S-f	Ethyl glut K2+ d metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite phydroxypentyl metabolite bentyl) metabolite bentyl) metabolite bentyl) metabolite bentyl) metabolite roxypentyl metabolite bentyl) metabolite roxypentyl metabolite roxypentyl metabolite roxypentyl metabolite roxypentyl metabolite roxypentyl metabolite bentyl metabolite tyl) metabolite tyl) metabolite tyl) metabolite bentyl metabolite tyl) metabolite roxypentyl metabolite tyl) metabolite tyl) metabolite bentyl metabolite tyl) metabolite	idem (ZOL50) athinone (MCAT) Mephadrone Cathinone hedrone (MEP) Methoattinone Cathinone	420 270
AM2201 N-(4-hydroxypent IWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA Pentanoic aci AB-PINACA N-(4-hydroxybut AB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(5-hydroxy I-march AB-PINACA AB-PI	Ethyl glue K2+ d metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite pontyl) metabolite bentyl) metabolite tabolite tabolite tabolite tyl) metabolite Zolg ylic acid Methor 1,000 10,000 500 100,000 UR-1-	oldem (ZOL50) antinone (MECAT) Mephadrone Cathinone Methathinone	420 270
AM2201 N-(4-hydroxypent IWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA Pentanoic acid AB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(5-hydroxy B-fluora AB-PINACA AB-PINACA N-(5-hydroxy B-fluora AB-PINACA AB-PINACA N-(5-hydroxy B-fluora AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA B-Fluora AB-PINACA AB-PI	Ethyl glut K2+ d metabolite bentyl) metabolite pentyl) metabolite pypentyl) metabolite pypentyl) metabolite pypentyl) metabolite pypentyl) metabolite pypentyl) metabolite pypentyl) metabolite pentyl) metabolite pypentyl metabolite pylic acid Me-PINACA) All pylic acid Methcc pylic acid pylic	idem (ZOL50) athinone (MCAT) Mephadrone Cathinone hedrone (MEP) Methoattinone Cathinone	420 270
AM2201 N-(4-hydroxypent IWH-073 N-(3-hydroxybut Ethyl glucuronide AB-PINACA Pentanoic acid AB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(4-hydroxy ADB-PINACA N-(5-hydroxy B-fluora AB-PINACA AB-PINACA N-(5-hydroxy B-fluora AB-PINACA AB-PINACA N-(5-hydroxy B-fluora AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA AB-PINACA B-Fluora AB-PINACA AB-PI	Ethyl glur K2+ d metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite bentyl) metabolite tabolite tabolite Zolg ylic acid Method 1,000 >100,000 Mepl 500 >100,000 UR-1: betabolite etabolite etabolite	idem (ZOL50) athinone (MCAT) Meghedrone Cathinone hedrone Cathinone Ad (UR-144-25)	420 270
AM2201 N(4-hydroxypent WH-073 N(3-hydroxybut Ethyl glucuronide AB-PINACA Pentanoic aci AB-PINACA N(4-hydroxy ADB-PINACA N(4-hydrox ADB-PINACA N(4-hydrox ADB-PINACA N(4-hydrox ADB-PINACA N(5-hydrox) Filuror AB-PINACA N(4-hydrox AB-PINACA N(5-hydrox) Filuror AB-PINACA N(4-hydrox AB-PINACA N(5-hydrox) Filuror AB-PINACA AB-FINACA N(5-hydrox) Filuror AB-PINACA AB-PINACA (AKB-48) AB-PINACA (AKB-48) APINACA (AK	Ethyl glux K2+ d metabolite bentyl) metabolite ypentyl) metabolite ypentyl) metabolite ypentyl) metabolite pontyl) metabolite bentyl) metabolite bentyline metabolite bentyl) metabolite bentyl) metabolite bentyl) metabolite bentyl) metabolite bentyl) metabolite bentyl) metabolit	idem (ZOL50) athinone (MCAT) Mephadrone Cathinone hedrone (MEP) Methoattinone Cathinone	420 270

Effect of Urinary Specific Gravity

Fifteen (15) urine samples of normal, high, and low specific gravity ranges (1.000-1.037) were spiked with drugs at 50% below and 50% above cut-off levels respectively. The Multi-Drug Rapid Test Panel was tested in duplicate using fifteen drug-free urine and spiked urine samples. The results demonstrate that varying ranges of urinary specific gravity do not affect the test results.

Effect of Urinary Ph

The pH of an aliquoted negative urine pool was adjusted to a pH range of 5 to 9 in 1 pH unit increments and spiked with drugs at 50% below and 50% above cut-off levels. The spiked, pH-adjusted urine was tested with the Multi-Drug Rapid Test Panel. The results demonstrate that varying ranges of pH on tol interfere with the performance of the test.

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free urine or drug positive urine containing, Amphetamine, Barbiturates, Benzodiazepines, Buprenorphine, Cocaine, Marijuana, Methadone, Methamphetamine, Methyline, Tramadol, Ketamine, Phenorycidine, Propoxyphene, Tricycla, Oxycodone, Cotinine, EDDP, Fentanyl, Synthetic, Marijuana, Ethyl Glucuronide, K2+, Zolpidem, Methcathinone, Mephedrone, UR-144 or Lysergic acid diethylamice. The following compounds show no cross-reactivity when tested with the Multi-Drug Rapid Test Panel at a concentration of 100µg/mL.

Non Cross-Reactive Compounds

τουμg/mL.			
	Non Cross	Reacting Compounds	
Acetophenetidin	Dextromethorphan	3-Hydroxytyramine	Quinidine
Acetylsalicylic acid	Diclofenac	Isoxsuprine	Quinine
Aminopyrine	Diflunisal	Ketoprofen	Salicylic acid
Ampicillin	Digoxin	Labetalol	Serotonin
Apomorphine	Diphenhydramine	Loperamide	Sulfamethazine
Aspartame	Ethyl-p-aminobenzoate	Nalidixic acid	Sulindac
Atropine	β-Estradiol	Norethindrone	Tetracycline
Benzilic acid	Estrone-3-sulfate	Noscapine	Tetrahydrozoline
Benzoic acid	Erythromycin	d,I-Octopamine	Thiamine
Bilirubin	Furosemide	Oxalic acid	Thioridazine
Chloramphenicol	Gentisic acid	Oxolinic acid	Tolbutamide
Chlorpromazine	Hemoglobin	Oxymetazoline	Triamterene
Cholesterol	Hydralazine	Penicillin-G	Trimethoprim
Cortisone	Hydrochlorothiazide	Perphenazine	d,I-Tryptophan
Creatinine	Hydrocortisone	Phenelzine	Uric acid
Deoxycorticosterone	o-Hydroxyhippuric acid	Prednisone	Verapamil

Deoxycorticosterone o-t-Hydroxyhippuric acid Prednisone Verapamil

EIBLIOGRAPHY*

1. Hanke RL, CN Chiang, Urine Testing for Drugs of Abuse. National Institute for Drug Abuse (NIDA), Research Monograph 73, 1986.

2. Tietz NW. Textbook of Clinical Chemistry, W.B. Saunders Company, 1986; 1735.

3. Stewart DJ, Inaba T, Lucassen M, Kalow W. Clin. Pharmacol. Ther. April 1979; 25 ed: 464, 264-8.

4. Ambre J. J. Aral. Toxicot.1985; 9:241.

5. Winger, Gail, A Handbook of Drug and Achonol Abuse, Third Edition, Oxford Press, 1992, page 146.

6. Robert DeCresce. Drug Testing in the workplace, 1989 page 114.

7. Glass, IB. The International Handbook of Addiction Behavior. Routledge Publishing, New York, NY. 1991; 216

8. Cody, J.T., "Specimen Adulteration in drug uninalysis. Forensic Sci. Rev., 1990, 2:63.

9. C. Tsal, S.C. et al., J. Anal. Toxicol. 1998; 22 (6): 474

10. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 6th Ed. Biomedical Publ., Foster City, CA 2002.

11. Hardman JG, Limbird LE. Goodman and Gilman's: The Pharmacological Basis for Therapeutics. 10th Edition. McGraw Hill Medical Publishing, 2001; 208-209.

12. J.H. Lewis and J.H. Vine. "A Simple and Rapid Method for the Identification of Zolpidem Carboxylic Acid in Urine." Journal of Analytical Toxicology, Vol. 31, May 2007.

13. SALVAP.COSTAJ. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications! J. Clinicharmacokineti, 1995, 29(3): 142-153.

14. Libong J, bouchonnet S, Ricordel I. A Selective and Sensitive Method for Quantitation of Lysergic Acid Diethylamide (LSD) in Whole Blood by Gas Chromatography-Ion Trap Tandem Mass Spectrometry(J), Journal of Analytical Toxicology, 2003, (27): 24-29.

15. Burmley BT, George S. The Development and Application of a Gas Chromatography-Mass Spectrometric(GC/MS) Assay to Determine the Presence of 2-oxo-3-hydroxy-LSD in urine[J], Journal of Analytical Toxicology, 2003, (27): 249-252 Index of Symbols

		IIIGEX OI	Cymbols			
i	Consult Instruction for use	\sum	Tests per kit		EC REP	Authorized Representative
IVD	For <i>in vitro</i> diagnostic use only	\geq	Use by		(29)	Do not reuse
210 - 3010	Store between 2-30°C	LOT	Lot Number		REF	Catalog #
\text{\ti}\\\ \text{\texi{\text{\texi{\text{\tex{\tex	Do not use if package is damaged					
_				E	C REP	

Hangzhou Biotest Biotech Co., Ltd.
17#, Futal Road, Zhongtal Street,
Vuhang District, Hangzhou, P. R. China

Line Carp. GmbH (Europe)
Effications 2037 Hamburg, Germany

Number: RP5509500 Effective date: 2023-03-20